29. Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, Hwu HG. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. *Am J Psychiatry.* 1998;155(9):1214-1220.
30. Bucholz KK, Cadoret R, Cloninger CR, Dinwiddie SH, Hesselbrock VM, Nurnberger JI Jr, Reich T, Schmidt I, Schuckit MA. A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA. *J Stud Alcohol.* 1994;55(2):149-158.
31. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders.* 4th ed. Washington, DC: American Psychiatric Association; 1994.
32. Liu QR, Drgon T, Johnson C, Walther D, Hess J, Uhl GR. Addiction molecular genetics: 639,401 SNP whole genome association identifies many "cell adhesion" genes. *Am J Med Genet B Neuropsychiatr Genet.* 2006;141(8):918-925.
33. Itoh K, Hashimoto K, Shimizu E, Sekine Y, Ozaki N, Inada T, Harano M, Iwata N, Komiyama T, Yamada M, Sora I, Nakata K, Ujike H, Iyo M. Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. *Am J Med Genet B Neuropsychiatr Genet.* 2005;132(1):70-73.
34. Iwata N, Inada T, Harano M, Komiyama T, Yamada M, Sekine Y, Iyo M, Sora I, Ujike H, Ozaki N. No association is found between the candidate genes of t-PA/plasminogen system and Japanese methamphetamine-related disorder: a collaborative study by the Japanese Genetics Initiative for Drug Abuse. *Ann N Y Acad Sci.* 2004;1025:34-38.
35. Morita Y, Ujike H, Tanaka Y, Uchida N, Nomura A, Ohtani K, Kishimoto M, Morio A, Imamura T, Sakai A, Inada T, Harano M, Komiyama T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. *Neurosci Lett.* 2005;376(3):182-187.
36. Hashimoto T, Hashimoto K, Matsuzawa D, Shimizu E, Sekine Y, Inada T, Ozaki N, Iwata N, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Iyo M. A functional glutathione S-transferase P1 gene polymorphism is associated with methamphetamine-induced psychosis in Japanese population. *Am J Med Genet B Neuropsychiatr Genet.* 2005;135(1):5-9.
37. Ujiie H, Inada T, Harano M, Komiyayama T, Yamada M, Sekine Y, Sora I, Iwata N, Iyo M, Ozaki N. Genetic studies on substance dependence [in Japanese]. *Seishin Shinkeigaku Zasshi.* 2004;106(12):1598-1603.
38. Nishiyama T, Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Inada T, Furukawa T, Ozaki N. Haplotype association between GABAA receptor gamma2 subunit gene (GABRG2) and methamphetamine use disorder. *Pharmacogenomics J.* 2005;5(2):89-95.
39. Morita Y, Ujike H, Tanaka Y, Uchida N, Nomura A, Otani K, Kishimoto M, Morio A, Inada T, Harano M, Komiyama T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N. The X-box binding protein 1 (XBP1) gene is not associated with methamphetamine dependence. *Neurosci Lett.* 2005;383(1-2):194-198.
40. Ikeda M, Iwata N, Suzuki T, Kitajima T, Yamanouchi Y, Kinoshiya Y, Sekine Y, Iyo M, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Inada T, Ozaki N. Positive association of AKT1 haplotype to Japanese methamphetamine use disorder [published online ahead of print June 28, 2005]. *Int J Neuropsychopharmacol.* 2006;9(1):77-81.
41. Ide S, Kobayashi H, Tanaka K, Ujike H, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Iyo M, Ikeda K, Sora I. Gene polymorphisms of the mu opioid receptor in methamphetamine abusers. *Ann N Y Acad Sci.* 2004;1025:316-324.
42. Harano M, Uchimura N, Abe H, Ishibashi M, Iida N, Yanagimoto K, Tanaka T, Maeda H, Sora I, Iyo M, Komiyama T, Yamada M, Sekine Y, Inada T, Ozaki N, Ujike H. A polymorphism of DRD2 gene and brain atrophy in methamphetamine psychosis. *Ann N Y Acad Sci.* 2004;1025:307-315.
43. Inada T, Iijima Y, Uchida N, Maeda T, Iwashita S, Ozaki N, Harano M, Komiyama T, Yamada M, Sekine Y, Iyo M, Sora I, Ujikec H. No association found between the type 1 sigma receptor gene polymorphisms and methamphetamine abuse in the Japanese population: a collaborative study by the Japanese Genetics Initiative for Drug Abuse. *Ann N Y Acad Sci.* 2004;1025:27-33.
44. Koizumi H, Hashimoto K, Kumakiri C, Shimizu E, Sekine Y, Ozaki N, Inada T, Harano M, Komiyama T, Yamada M, Sora I, Ujike H, Takei N, Iyo M. Association between the glutathione S-transferase M1 gene deletion and female methamphetamine abusers. *Am J Med Genet B Neuropsychiatr Genet.* 2004;126(1):43-45.
45. Ujike H, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, Sora I, Iyo M, Katsu T, Nomura A, Nakata K, Ozaki N. Nine or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. *Pharmacogenomics J.* 2003;3(4):242-247.
46. World Health Organization. *ICD-10: International Statistical Classification of Diseases and Related Health Problems: Tenth Revision.* 2nd ed. Geneva, Switzerland: World Health Organization; 2004.
47. Smith SS, O'Hara BF, Persico AM, Gorelick DA, Newlin DB, Vlahov D, Solomon L, Pickens R, Uhl GR. Genetic vulnerability to drug abuse: the D2 dopamine receptor Taq I B1 restriction fragment length polymorphism appears more frequently in polysubstance abusers. *Arch Gen Psychiatry.* 1992;49(9):723-727.
48. Persico AM, Bird G, Gabbay FH, Uhl GR. D2 dopamine receptor gene Taql A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. *Biol Psychiatry.* 1996;40(8):776-784.
49. Mägi R, Pfeufer A, Nelis M, Montpetit A, Metspalu A, Remm M. Evaluating the performance of commercial whole-genome marker sets for capturing common genetic variation. *BMC Genomics.* 2007;8:159.
50. Wilkening S, Chen B, Wirtenberger M, Burwinkel B, Forsti A, Hemminki K, Canzian F. Allelotyping of pooled DNA with 250 K SNP microarrays. *BMC Genomics.* 2007;8:77.
51. Macgregor S, Visscher PM, Montgomery G. Analysis of pooled DNA samples on high density arrays without prior knowledge of differential hybridization rates. *Nucleic Acids Res.* 2006;34(7):e55.
52. Liu QR, Drgon T, Walther D, Johnson C, Poleskaya O, Hess J, Uhl GR. Pooled association genome scanning: validation and use to identify addiction vulnerability loci in two samples. *Proc Natl Acad Sci U S A.* 2005;102(33):11864-11869.
53. Meaburn E, Butcher LM, Schalkwyk LC, Plomin R. Genotyping pooled DNA using 100K SNP microarrays: a step towards genomewide association scans. *Nucleic Acids Res.* 2006;34(4):e27.
54. Butcher LM, Meaburn E, Knight J, Sham PC, Schalkwyk LC, Craig IW, Plomin R. SNPs, microarrays and pooled DNA: identification of four loci associated with mild mental impairment in a sample of 6000 children. *Hum Mol Genet.* 2005;14(10):1315-1325.
55. Papassotiropoulos A, Stephan DA, Huentelman MJ, Hoerndli FJ, Craig DW, Pearson JV, Huynh KD, Brunner F, Corneveaux J, Osborne D, Wollmer MA, Aerni A, Coluccia D, Hanggi J, Mondadori CR, Buchmann A, Reiman EM, Caselli RJ, Henke K, de Quervain DJ. Common Kibra alleles are associated with human memory performance. *Science.* 2006;314(5798):475-478.
56. Bansal A. Trends in reporting of SNP associations. *Lancet.* 2001;358(9298):2016.
57. Johnson C, Drgon T, Liu QR, Walther D, Edenberg H, Rice J, Foroud T, Uhl GR. Pooled association genome scanning for alcohol dependence using 104,268 SNPs: validation and use to identify alcoholism vulnerability loci in unrelated individuals from the collaborative study on the genetics of alcoholism. *Am J Med Genet B Neuropsychiatr Genet.* 2006;141(8):844-853.
58. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF, Swan GE, Rutter J, Bertelsen S, Fox L, Fugman D, Goate AM, Hinrichs AL, Konvicka K, Martin NG, Montgomery GW, Saccone NL, Saccone SF, Wang JC, Chase GA, Rice JP, Ballinger DG. Novel genes identified in a high-density genome wide association study for nicotine dependence. *Hum Mol Genet.* 2007;16(1):24-35.
59. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, Rose JE. Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. *BMC Genet.* 2007;8(1):10.
60. Dupont WD, Plummer WD Jr. Power and sample size calculations: a review and computer program. *Control Clin Trials.* 1990;11(2):116-128.
61. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics.* 2003;19(1):149-150.
62. Butcher LM, Meaburn E, Liu L, Fernandes C, Hill L, Al-Chalabi A, Plomin R, Schalkwyk L, Craig IW. Genotyping pooled DNA on microarrays: a systematic genome screen of thousands of SNPs in large samples to detect QTLs for complex traits. *Behav Genet.* 2004;34(5):549-555.
63. Hishimoto A, Liu QR, Drgon T, Pletnikova O, Walther D, Zhu XG, Troncoso JC, Uhl GR. Neurexin 3 polymorphisms are associated with alcohol dependence and altered expression of specific isoforms. *Hum Mol Genet.* 2007;16(23):2880-2891.
64. Ishiguro H, Liu QR, Gong JP, Hall FS, Ujike H, Morales M, Sakurai T, Grumet M, Uhl GR. NrCAM in addiction vulnerability: positional cloning, drug-regulation, haplotype-specific expression, and altered drug reward in knockout mice. *Neuropsychopharmacology.* 2006;31(3):572-584.
65. Takeuchi T, Misaki A, Liang SB, Tachibana A, Hayashi N, Sonobe H, Ohtsuki Y. Expression of T-cadherin (CDH13, H-Cadherin) in human brain and its characteristics as a negative growth regulator of epidermal growth factor in neuroblastoma cells. *J Neurochem.* 2000;74(4):1489-1497.
66. Fredette BJ, Miller J, Ranscht B. Inhibition of motor axon growth by T-cadherin substrata. *Development.* 1996;122(10):3163-3171.
67. Kipmen-Korgun D, Osibow K, Zoratti C, Schraml E, Greilberger J, Kostner GM, Jurgens G, Graier WF. T-cadherin mediates low-density lipoprotein-initiated cell proliferation via the Ca(2+)-tyrosine kinase-Erk1/2 pathway. *J Cardiovasc Pharmacol.* 2005;45(5):418-430.
68. Philippova M, Ivanov D, Allenspach R, Takuwa Y, Erne P, Resink T. RhoA and Rac mediate endothelial cell polarization and detachment induced by T-cadherin. *FASEB J.* 2005;19(6):588-590.

69. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. *Proc Natl Acad Sci U S A.* 2004;101(28):10308-10313.
70. Ivanov DB, Philippova MP, Tkachuk VA. Structure and functions of classical cadherins. *Biochemistry (Mosc).* 2001;66(10):1174-1186.
71. Yamakawa K, Huot YK, Haendelt MA, Hubert R, Chen XN, Lyons GE, Korenberg DSCAM Jr. A novel member of the immunoglobulin superfamily maps in a Down syndrome region and is involved in the development of the nervous system. *Hum Mol Genet.* 1998;7(2):227-237.
72. Barlow GM, Micales B, Lyons GE, Korenberg JR. Down syndrome cell adhesion molecule is conserved in mouse and highly expressed in the adult mouse brain. *Cytogenet Cell Genet.* 2001;94(3-4):155-162.
73. Chen BE, Kondo M, Garnier A, Watson FL, Puettmann-Holgado R, Lamar DR, Schmucker D. The molecular diversity of Dscam is functionally required for neuronal wiring specificity in Drosophila. *Cell.* 2006;125(3):607-620.
74. Keene AC, Krashes MJ, Leung B, Bernard JA, Waddell S. Drosophila dorsal paired medial neurons provide a general mechanism for memory consolidation. *Curr Biol.* 2006;16(15):1524-1530.
75. Feil S, Zimmermann P, Knorn A, Brummer S, Schlossmann J, Hofmann F, Feil R. Distribution of cGMP-dependent protein kinase type I and its isoforms in the mouse brain and retina. *Neuroscience.* 2005;135(3):863-868.
76. Demyanenko GP, Halberstadt AI, Pryzwansky KB, Werner C, Hofmann F, Maness PF. Abnormal neocortical development in mice lacking cGMP-dependent protein kinase I. *Brain Res Dev Brain Res.* 2005;160(1):1-8.
77. Weitzdoerfer R, Hoeger H, Engidawork E, Engelmann M, Singewald N, Lubec G, Lubec B. Neuronal nitric oxide synthase knock-out mice show impaired cognitive performance. *Nitric Oxide.* 2004;10(3):130-140.
78. Itzhak Y, Martin JL, Black MD, Huang PL. The role of neuronal nitric oxide synthase in cocaine-induced conditioned place preference. *Neuroreport.* 1998; 9(11):2485-2488.
79. Kleppisch T, Wolfsgruber W, Feil S, Allmann R, Wotjak CT, Goebbels S, Nave KA, Hofmann F, Feil R. Hippocampal cGMP-dependent protein kinase I supports an age- and protein synthesis-dependent component of long-term potentiation but is not essential for spatial reference and contextual memory. *J Neurosci.* 2003; 23(14):6005-6012.
80. Allen Institute for Brain Science Allen Brain Atlas. http://brain-map.org/. Accessed January 23, 2007.
81. Underwood JG, Boutz PL, Dougherty JD, Stoilov P, Black DL. Homologues of the Caenorhabditis elegans Fox-1 protein are neuronal splicing regulators in mammals. *Mol Cell Biol.* 2005;25(22):10005-10016.
82. Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, Gunnarsdottir S, Walker N, Petursson H, Crombie C, Ingason A, Gulcher JR, Stefansson K, St Clair D. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. *Am J Hum Genet.* 2003;72(1):83-87.
83. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. *Am J Hum Genet.* 2002;71(4):877-892.
84. Stefansson H, Steinthorsdottir V, Thorgeirsson TE, Gulcher JR, Stefansson K. Neuregulin 1 and schizophrenia. *Ann Med.* 2004;36(1):62-71.
85. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature.* 2007; 447(7145):661-678.
86. Dudbridge F, Gusnanto A, Koeleman BP. Detecting multiple associations in genome-wide studies. *Hum Genomics.* 2006;2(5):310-317.
87. NHLBI Research and Policy Update, number 35, November 2006. www.nhlbi.nih.gov/resources/listserv/number35.htm. Accessed January 23, 2007.

Neuroscience Letters 438 (2008) 327–329

Contents lists available at ScienceDirect

Neuroscience Letters

journal homepage: www.elsevier.com/locate/neulet

Hyperthermic and lethal effects of methamphetamine: Roles of dopamine D1 and D2 receptors

Miki Ito, Yohtaro Numachi, Arihisa Ohara, Ichiro Sora*

Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8574, Japan

ARTICLE INFO

Article history:
Received 3 March 2008
Received in revised form 11 April 2008
Accepted 11 April 2008

Keywords:
Knockout mice
Body temperature

ABSTRACT

Both human and animal studies suggest that hyperthermia contributes to the lethal effects of methamphetamine. To elucidate the roles of dopamine D1 and D2 receptors in methamphetamine-induced hyperthermia and lethal effects, we used D1 knockout (D1KO) mice, D2 knockout (D2KO) mice, and wild-type littermates. After the administration (i.p.) of a single dose of 30 mg/kg methamphetamine, no hyperthermic effect on body temperature was observed in D2KO mice, though there was a slight elevation in D1KO mice and a marked elevation in wild-type mice. Approximately 27% of the wild-type mice died after the administration, compared to only 7% of D1KO mice and 4% of D2KO mice. In conclusion, both D1 and D2 receptors play roles in the lethal toxic effects of methamphetamine, and mainly the D2 receptor is involved in the elevation of body temperature.

Methamphetamine, a drug of abuse known worldwide for its addictive effects and neurotoxicity, causes somatic and psychiatric disorders. Methamphetamine can cause death in humans, non-human primates, and rodents [6,12,19]. As one of its acute symptoms, methamphetamine-induced hyperthermia which is observed in both human and animals, could contribute to the lethal effects of methamphetamine.

Methamphetamine enters terminals/neurons via monoamine transporters, displaces both vesicular and intracellular monoamines, and facilitates the release of monoamines into the extraneuronal space through synaptic transport via the monoamine transporters [15]. Studies in animals suggest that the activation of dopamine receptors is crucial for methamphetamine-induced hyperthermia [1,4,9,10] and death [5,16]. However, the protective roles of dopamine receptor antagonists against methamphetamine-induced hyperthermia and lethal effects are affected by doses of antagonists and/or methamphetamine, and ambient temperature.

The lethal effect of methamphetamine was diminished by pretreatment with the neuroleptic agent haloperidol [17], the selective D1 receptor antagonist SCH23390 [11], or the D2 receptor antagonist spiperone [5]. By contrast, some have reported that no alteration was demonstrated on pretreatment with SCH23390 [8] or haloperidol [7], and the lethal effect was actually enhanced by pretreatment with sulpiride, a D2 receptor antagonist [5].

Similarly, there are discrepancies in results regarding the prevention of methamphetamine-induced hyperthermia through pretreatment with antagonists; some studies reported preventive roles of haloperidol [9], SCH23390 [4], and eticlopride, a selective D2 antagonist [4] while others showed no effect of SCH23390, and raclopride, selective D2 antagonists [5,18] In this study, we examined the roles of D1 and D2 receptors in the hyperthermic and lethal effects of methamphetamine using D1 knockout (D1KO) and D2 knockout (D2KO) mice.

D1KO mice (The Jackson Laboratory, Maine, USA), D2KO mice (The Jackson Laboratory), and wild-type littermates, 15 ± 2 (average ± S.D.) weeks old, were maintained under conditions of controlled temperature and lighting, with food and water provided *ad libitum* (genetic background was C57BL/129Sv for all genotypes). The mice were habituated one day prior to the experiments in a temperature-controlled chamber (22 ± 1 °C; light 8:00–20:00; LP-30CCFL-8AR, Nippon Medical and Chemical Instruments CO., LTD., Osaka, Japan), and all the experiments were performed with this chamber. Seventy-one wild-type mice, 21 D1KO mice, and 23 D2KO mice were intraperitoneally (i.p.) administered 30 mg/kg of d-methamphetamine (Dainippon Sumitomo Pharmaceuticals Co., Ltd., Osaka, Japan), while 47 wild-type mice, 27 D1KO mice, and 12 D2KO mice were treated saline (i.p.). To exclude effects of circadian rhythm, mice were administered either saline or methamphetamine from 16:00 to 17:30. The maintenance and testing of animals were carried out in accordance with the guidelines of the animal ethics committee at Tohoku University Graduate School of Medicine, Japan.

* Corresponding author. Tel.: +81 22 717 7808; fax: +81 22 717 7809.
E-mail address: isora@mail.tains.tohoku.ac.jp (I. Sora).

0304-3940/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.neulet.2008.04.034

Table 1
Lethality and highest temperature in the three genotypes

Genotype	Lethality% (died/total)		Highest temperature °C (*n*)
D1KO	7* (2/29)	Survived	38.8 ± 0.21 (27)
		Died	40.3 ± 0.75 (2)
D2KO	4* (1/23)	Survived	38.2 ± 0.27 (22)
		Died	39.2 (1)
Wild-type	27 (19/71)	Survived	39.9 ± 0.12 (52)
		Died	40.7 ± 0.32 (19)**

Mice were given 30 mg/kg of methamphetamine (i.p.). Rectal temperature was measured just before (0 min), and 30 and 60 min after the administration. Lethality was significantly lower in D1KO and D2KO mice than wild-type mice (Fisher's exact test, $^{*}p < 0.05$). In all genotypes, the highest temperatures were higher in dead mice, especially wild-type mice (Student's *t*-test, $^{**}p < 0.05$).



Fig. 1. Effect of a single dose of methamphetamine (MAP) at 30 mg/kg on temperature in mice. MAP extensively increased temperature through three-time points in wild-type mice ($^{*}p < 0.001$ compared to saline-treated wild-type mice, $^{**}p < 0.001$ compared to MAP-treated wild-type mice at 30 min). MAP increased temperature in D1KO mice ($^{*}p < 0.001$ compared to saline-treated D1KO mice), although it leveled off after 30 min. There was no significant difference between saline and MAP treatments in D2KO mice. At 30 min, the temperature of MAP-treated D2KO mice was significantly lower than that of MAP-treated wild-type mice ($^{\#}p < 0.001$). At 60 min, temperature was significantly lower in both D1KO and D2KO mice treated with MAP than in wild-type mice ($^{\#\#}p < 0.001$). Figures in parentheses represent numbers of mice. Values represent the mean ± S.E.M.

Core body temperature was determined using an electronic thermometer (BAT-10, Physitemp Instruments, New Jersey, USA) with a rectal probe (RET-3, Physitemp Instruments) three times just before (0 min) and at 30 and 60 min after drug administration. We chose 60 min time period based on our preliminary experiments (unpublished) and previous report [18]. To evaluate lethality, we counted the number of mice that died within 24 h after methamphetamine treatment. The data on temperature from mice which died within 60 min were excluded.

The data represent means ± S.E.M. Statistical analyses were performed using a one-way analysis of variance (ANOVA) for rectal temperature. For post hoc comparisons, Tukey's HSD test was used for comparison of methamphetamine-treated with saline-treated controls of same genotype, comparison of time condition in same treatment and genotype, and comparison among genotypes. Fisher's exact test was applied for lethality. The criterion of statistical significance was set at $p < 0.05$.

At 30 mg/kg, methamphetamine was significantly less lethal in D1KO mice (7%) and D2KO mice (4%) than in the wild-type mice (27%). Two wild-type mice died within 30 min followed by six wild-type mice within 60 min, and 11 wild-type mice within 24 h. On the other hand, one D1KO mouse died within 30 min, one D1KO mouse died within 60 min, and one D2KO mouse died within 24 h. Means of highest temperatures of the dead mice were higher than those of the surviving mice (Table 1).

Body temperature in wild-type mice hit 39.2 °C at 30 min and kept rising and exceeded 40.1 °C at 60 min after methamphetamine's administration. Both temperatures are significantly higher than that of saline-treated wild-type mice ($p < 0.001$), and the temperature at 60 min was higher than that of at 30 min ($p < 0.001$). Body temperature in D1KO mice also rose to 38.5 °C at 30 min by methamphetamine, although it leveled off after 30 min and ended with 38.4 °C at 60 min. While in D2KO mice, there was no significant increase of body temperature induced by methamphetamine and the temperatures at 30 min (37.8 °C) and 60 min (37.5 °C) were significantly lower than that of wild-type mice (Fig. 1). Although D1KO mice showed methamphetamine-induced rise in body temperature, its absolute temperature was not significantly different from that of D2KO at any time point, and body temperatures at 60 min was significantly lower than that of wild-type mice ($p < 0.001$). Overall, methamphetamine-induced net increase of body temperature was highest in wild-type mice (3.5 °C), followed by D1KO mice (2.1 °C).

The body temperature of the wild-type mice which died from methamphetamine treatment was significantly higher than that of the survivors (Table 1). The body temperature of the D1KO or D2KO mice which died was also higher than that of surviving mice. The difference in body temperature between the dead and surviving D1KO or D2KO mice did not reach a level of statistical significance however, the number of dead mice being too small.

The present results indicate that these subtypes of dopamine receptors work similarly in lethal effects and differently in the hyperthermic effects of methamphetamine. Our results showed that methamphetamine exerts a lethal effect via D1 and D2 receptors, because deletion of these receptors in mice significantly decreased the toxicity of methamphetamine within 24 h after the drug treatment. A previous paper stated that the activation of the D1 receptor is an important event in the lethality caused by methamphetamine [5]. Our study suggested the importance of the D2 receptor, along with the D1 receptor, in the lethal toxicity of methamphetamine.

The absence of methamphetamine-induced hyperthermia in our study with D2KO mice may suggest that the D2 receptor plays a major role in inhibiting methamphetamine-induced hyperthermia. The lower basal body temperature of D1KO mice seemed to attenuate the hyperthermic effect induced by methamphetamine, although there was a notable difference in the net increase in body temperature between the wild-type and D1KO mice. Moreover, the result that D1KO mice did not continuously rise its temperature and settled at lower temperature than wild-type mice implies that D1 receptor takes roles in causing latter and serious hyperthermia by methamphetamine differently from D2 receptor. There are also possibilities that levels of D2 or D1 receptor expression or function, especially in hypothalamus, might be affected in D1KO mice or D2KO mice, respectively.

The body temperature of the wild-type mice which died following methamphetamine treatment was significantly higher than that of the mice which survived in our study. The body temperature of the average of the two died D1KO mice or the one died D2KO mouse was also higher than that of the mice which survived in respective genotypes. Note that the number of dead mice was too small to apply statistic analysis. The body temperature of rats treated with methamphetamine exceeded 41 °C [2], whereas animals placed on ice survived from hyperthermia caused by methamphetamine or the coadministration of methamphetamine and morphine [3,13,14]. The lethal effect of methamphetamine could be prevented by controlling body temperature.

In summary, the results of the present study suggest both D1 receptor and D2 receptor take roles in the lethal effect of metham-

phetamine. These two subtypes work differently in hyperthermic effects of methamphetamine. Since D2KO mice completely eliminated methamphetamine-induced hyperthermia, D2 receptor may take acute and major roles in methamphetamine-induced hyperthermia. While D1KO mice did not let the temperature hit the serious level, D1 receptor may take roles in later stage in 60 min and crucial hyperthermia. Elucidating the roles of these receptors in the toxicity of methamphetamine should help in the development of novel medications and treatments.

Acknowledgements

We thank Dr. Hideaki Kobayashi for technical advice and discussions. This study was supported by a Grant-in-aid for Health and Labour Science Research (Research on Pharmaceutical and Medical Safety) from the Ministry of Health, Labour and Welfare of Japan; and by Grants-in-aid for Scientific Research on Priority Areas – System study on higher-order brain functions and Research on Pathomechanisms of Brain Disorders – from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 17022007, 18023007).

References

[1] D.S. Albers, P.K. Sonsalla, Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents, J. Pharmacol. Exp. Ther. 275 (1995) 1104–1114.
[2] J.F. Bowyer, D.L. Davies, L. Schmued, H.W. Broening, G.D. Newport, W. Slikker Jr., R.R. Holson, Further studies of the role of hyperthermia in methamphetamine neurotoxicity, J. Pharmacol. Exp. Ther. 268 (1994) 1571–1580.
[3] J.F. Bowyer, A.W. Tank, G.D. Newport, W. Slikker Jr., S.F. Ali, R.R. Holson, The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum, J. Pharmacol. Exp. Ther. 260 (1992) 817–824.
[4] H.W. Broening, L.L. Morford, C.V. Vorhees, Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions, Synapse 56 (2005) 84–93.
[5] D.M. Bronstein, J.S. Hong, Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality, J. Pharmacol. Exp. Ther. 274 (1995) 943–950.
[6] C. Davidson, A.J. Gow, T.H. Lee, E.H. Ellinwood, Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment, Brain Res. Brain Res. Rev. 36 (2001) 1–22.
[7] R.W. Derlet, T.E. Albertson, P. Rice, Antagonism of cocaine, amphetamine, and methamphetamine toxicity, Pharmacol. Biochem. Behav. 36 (1990) 745–749.
[8] R.W. Derlet, T.E. Albertson, P. Rice, The effect of SCH 23390 against toxic doses of cocaine, d-amphetamine and methamphetamine, Life Sci. 47 (1990) 821–827.
[9] M. Funahashi, H. Kohda, O. Hori, H. Hayashida, H. Kimura, Potentiating effect of morphine upon d-methamphetamine-induced hyperthermia in mice. Effects of naloxone and haloperidol, Pharmacol. Biochem. Behav. 36 (1990) 345–350.
[10] J. He, H. Xu, Y. Yang, X. Zhang, X.M. Li, Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats, Brain Res. 1018 (2004) 186–192.
[11] L.C. Iorio, A. Barnett, F.H. Leitz, V.P. Houser, C.A. Korduba, SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems, J. Pharmacol. Exp. Ther. 226 (1983) 462–468.
[12] H. Kalant, O.J. Kalant, Death in amphetamine users: causes and rates, Can. Med. Assoc. J. 112 (1975) 299–304.
[13] M.J. LaVoie, T.G. Hastings, Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine, J. Neurosci. 19 (1999) 1484–1491.
[14] M. Namiki, T. Mori, T. Sawaguchi, S. Ito, T. Suzuki, Underlying mechanism of combined effect of methamphetamine and morphine on lethality in mice and therapeutic potential of cooling, J. Pharmacol. Sci. 99 (2005) 168–176.
[15] L.S. Seiden, K.E. Sabol, G.A. Ricaurte, Amphetamine: effects on catecholamine systems and behavior, Annu. Rev. Pharmacol. Toxicol. 33 (1993) 639–677.
[16] E. Uchima, Y. Ogura, Y. Hiraga, I. Shikata, Relationship between methamphetamine toxicity and catecholamine levels in heart and brain of mice, Nihon Hoigaku Zasshi 37 (1983) 198–208.
[17] J.M. Witkin, S.R. Goldberg, J.L. Katz, Lethal effects of cocaine are reduced by the dopamine-1 receptor antagonist SCH 23390 but not by haloperidol, Life Sci. 44 (1989) 1285–1291.
[18] W. Xu, J.P. Zhu, J.A. Angulo, Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors, Synapse 58 (2005) 110–121.
[19] J. Yuan, G. Hatzidimitriou, P. Suthar, M. Mueller, U. McCann, G. Ricaurte, Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys, J. Pharmacol. Exp. Ther. 316 (2006) 1210–1218.

MONOAMINE TRANSPORTER AS A TARGET MOLECULE FOR PSYCHOSTIMULANTS

Ichiro Sora,* BingJin Li,* Setsu Fumushima,* Asami Fukui,* Yosefu Arime,* Yoshiyuki Kasahara,* Hiroaki Tomita,* and Kazutaka Ikeda†

*Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, Sendai 980–8574, Japan

†Molecular Psychiatry Research, Tokyo Institute of Psychiatry, Tokyo 156–8585, Japan

Methamphetamine (MAP), a drug of abuse known worldwide for its addictive effects and neurotoxicity, causes somatic and psychiatric disorders. MAP enters terminals/neurons via monoamine transporters, displaces both vesicular and intracellular monoamines, and facilitates the release of monoamines into the extraneuronal space through synaptic transport via the monoamine transporters. Chronic psychostimulant abusers exhibit psychotic features, including delusions and auditory hallucinations. The dopamine transporter (DAT) and the vesicular monoamine transporter 2 (VMAT2) play pivotal roles in the action of MAP, including locomotor effects. The deletion of DAT attenuates the locomotor effects of MAP and may play larger role in behavioral responses to MAP compared to the deletion of VMAT2. MAP produces hyperthermia and/or neuronal toxicity in most species. The effects of MAP in DAT or serotonin transporter (SERT) single knockout (KO) mice and DAT/SERT double KO mice suggested that DAT and SERT are key molecules for hyperthermia and neuronal toxicity of MAP.

I. Introduction

Methamphetamine (MAP) is a psychostimulant that induces enhanced arousal and euphoria acutely, and psychosis and addiction chronically. MAP enters the terminals/neuron via the monoamine transporters (dopamine transporter: DAT, serotonin transporter: SERT, or norepinephrine transporter: NET), displaces

INTERNATIONAL REVIEW OF NEUROBIOLOGY, VOL. 85
DOI: 10.1016/S0074-7742(09)85003-4

0074-7742/09 $35.00

both vesicular and intracellular monoamines, and facilitates release of monoamines into the extraneuronal space by synaptic transport in the monoamine transporters (Seiden *et al.*, 1993). The large release of monoamine produced by psychostimulant is thought to contribute to the drug's effects in the brain.

II. MAP-Induced Behavioral Sensitization

The acute and chronic pharmacological consequences of MAP in human users have been observed in behavioral experiments in animals, including both hyperactivity and sensitization of locomotor responses (Segal and Schuckit, 1983). Behavioral sensitization is a phenomenon whereby repeated intermittent exposure to MAP-like psychostimulant elicits a progressive enhancement of those responses, which persists for extended time periods following withdrawal from the drug and are easily reinstated by exposure to the drug or psychosocial stress (Robinson and Becker, 1986). This process closely resembles the course of the relapse in MAP-induced psychosis or schizophrenia, thus sensitization in animals has been suggested to model these psychoses (Sato *et al.*, 1983). Behavioral sensitization is thought to be an early and enduring manifestation of neuronal plasticity associated with changes in mesolimbic dopamine neurotransmission (Kalivas *et al.*, 1993). MAP induces dopamine release through exchange diffusion of plasma membrane DAT (Seiden *et al.*, 1993), and release of vesicular dopamine into the cytosol by acting on the vesicular monoamine transporter 2 (VMAT2) (Sulzer *et al.*, 2005). The dopamine releasing effect of MAP has been postulated to mediate its locomotor stimulant and rewarding effects (White and Kalivas, 1998). Therefore, DAT and VMAT2 should play pivotal roles in the mechanisms underlying the actions of MAP.

DAT knockout (KO) mice and VMAT2 KO mice have been used to investigate the roles of DAT and VMAT2 in dopamine neurotransmission and pharmacological mechanisms underlying the actions of psychostimulants. Homozygous deletion of the DAT gene has been reported to produce a 10-fold increase (Shen *et al.*, 2004) or fivefold elevation (Jones *et al.*, 1998) of extracellular dopamine concentrations in the striatum measured by *in vivo* microdialysis, while heterozygous deletion of DAT was not found to significantly increase extracellular dopamine (Shen *et al.*, 2004) or to produce a smaller twofold elevation (Jones *et al.*, 1998) of dopamine in the striatum. Homozygous DAT KO mice show growth retardation and hyperactivity, whereas heterozygous DAT KO mice did not show gross abnormalities in either development or baseline behavioral parameters (Sora *et al.*, 1998). Habituated homozygous DAT KO mice do not show any significant cocaine-induced increase in locomotion (Sora *et al.*, 1998, 2001; Uhl *et al.*, 2002).

We examined locomotor activity and sensitization in heterozygous DAT KO ($DAT^{+/-}$), heterozygous VMAT2 KO ($VMAT2^{+/-}$), double heterozygous DAT/VMAT2 KO ($DAT^{+/-}$ $VMAT2^{+/-}$), and wild-type (WT) mice to evaluate the roles of DAT and VMAT2 in MAP-induced locomotor behavior (Fukushima *et al.*, 2007). In $DAT^{+/-}$ $VMAT2^{+/-}$ mice, all of MAP-induced behavioral responses were similar to those in $DAT^{+/-}$, but not $VMAT2^{+/-}$ mice. The behavioral effects of both acute and chronic MAP administration were suppressed in heterozygous DAT KO mice, whether or not it was combined with heterozygous VMAT2 KO. Contrary to the effect observed in heterozygous DAT KO mice, acute MAP administration produced greater locomotor responses in heterozygous VMAT2 KO mice. These findings indicate that the half deletion of DAT plays a major role in both acute and chronic behavioral responses to MAP, while the effect of the half deletion of VMAT2 is less prominent.

III. MAP-Induced Hyperthermia and Neuronal Toxicity

MAP abuse causes serious health hazards including irreversible neuronal degeneration, seizures, hyperthermia, and death in human and experimental animals (Davidson *et al.*, 2001). Among these side effects, MAP produces hyperthermia and/or dopaminergic neurotoxicity in most species. Clinical reports and animal studies indicate that lethality by MAP closely correlates with hyperthermia, which may be the primary cause of death. Animal studies suggest that dopamine receptor activation is crucial for MAP-induced hyperthermia (Broening *et al.*, 2005) and lethality (Bronstein and Hong, 1995). There has also been an assumption that the hyperthermia that follows MAP administration is serotonin receptor-mediated (Green *et al.*, 2003).

We examined hyperthermic and lethal toxic effects of MAP in DAT, SERT, and DAT/SERT double KO mice to elucidate the role of these two transporters in MAP-induced hyperthermia and lethality (Numachi *et al.*, 2007). MAP caused significant hyperthermia even in the mice with a single DAT gene copy and no SERT copies ($DAT^{+/-}$ $SERT^{-/-}$ mice). Mice with no DAT copies and a single SERT gene copy ($DAT^{-/-}$ $SERT^{+/-}$ mice) showed significant but reduced hyperthermia when compared to WT mice after MAP. These results demonstrate that MAP exerts a hyperthermic effect via DAT, or via SERT, in the absence of DAT. DAT gene deletion in mice strikingly increased LD_{50} of MAP by 1.7–1.8 times that of WT mice, suggesting that the lethal toxic effect of MAP is mainly dependent on DAT. Although DAT and SERT were shown here to be involved in both the effects of MAP on temperature as well as MAP lethal toxicity, the mechanisms are nonetheless different; DAT single KO mice exhibited hyperthermia but greatly reduced MAP lethality, and the lethality was no different from

DAT/SERT double KO mice that had hypothermic responses to MAP. Thus, although the lethal toxic effect of MAP is mainly dependent on DAT, with some contribution from SERT, hyperthermia is not prerequisite for MAP-induced lethality.

In conclusion, these findings lead us to hypothesize that DAT variants may have more profound effects than VMAT2 or SERT variants on the clinically important consequences of acute and chronic MAP abuse in humans.

Acknowledgments

This study was supported in part by Grant-in-Aid for Health and Labor Science Research (Research on Pharmaceutical and Medical Safety) from the Ministry of Health, Labor and Welfare of Japan; by Grants-in-Aid for Scientific Research (B), Scientific Research on Priority Areas—System study on higher order brain functions and Research on Pathomechanisms of Brain Disorders, Core Research for Evolutional Science and Technology (CREST), from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

References

Broening, H. W., Morford, L. L., and Vorhees, C. V. (2005). Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. *Synapse.* **56,** 84–93.

Bronstein, D. M., and Hong, J. S. (1995). Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality. *J. Pharmacol. Exp. Ther.* **274,** 943–950.

Davidson, C., Gow, A. J., Lee, T. H., and Ellinwood, E. H. (2001). Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment. *Brain Res. Brain Res. Rev.* **36,** 1–22.

Fukushima, S., Shen, H., Hata, H., Ohara, A., Ohmi, K., Ikeda, K., Numachi, Y., Kobayashi, H., Hall, F. S., Uhl, G. R., and Sora, I. (2007). Methamphetamine-induced locomotor activity and sensitization in dopamine transporter and vesicular monoamine transporter 2 double mutant mice. *Psychopharmacology (Berl.)* **193,** 55–62.

Green, A. R., Mechan, A. O., Elliott, J. M., O'Shea, E., and Colado, M. I. (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). *Pharmacol. Rev.* **55,** 463–508.

Jones, S. R., Gainetdinov, R. R., Jaber, M., Giros, B., Wightman, R. M., and Caron, M. G. (1998). Profound neuronal plasticity in response to inactivation of the dopamine transporter. *Proc. Natl. Acad. Sci. USA* **95,** 4029–4034.

Kalivas, P. W., Sorg, B. A., and Hooks, M. S. (1993). The pharmacology and neural circuitry of sensitization to psychostimulants. *Behav. Pharmacol.* **4,** 315–334.

Numachi, Y., Ohara, A., Yamashita, M., Fukushima, S., Kobayashi, H., Hata, H., Watanabe, H., Hall, F. S., Lesch, K. P., Murphy, D. L., Uhl, G. R., and Sora, I. (2007). Methamphetamine-

induced hyperthermia and lethal toxicity: Role of the dopamine and serotonin transporters. *Eur. J. Pharmacol.* **572,** 120–128.

Robinson, T. E., and Becker, J. B. (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: A review and evaluation of animal models of amphetamine psychosis. *Brain Res.* **396,** 157–198.

Sato, M., Chen, C. C., Akiyama, K., and Otsuki, S. (1983). Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. *Biol. Psychiatry* **18,** 429–440.

Segal, D. S., and Schuckit, M. A. (1983). Animal models of stimulant-induced psychosis. *In* "Stimulants: Neurochemical, Behavioral and Clinical Perspectives" (I. Grees, ed.), pp. 131–167. Reven, New York.

Seiden, L. S., Sabol, K. E., and Ricaurte, G. A. (1993). Amphetamine: Effects on catecholamine systems and behavior. *Annu. Rev. Pharmacol. Toxicol.* **33,** 639–677.

Shen, H. W., Hagino, Y., Kobayashi, H., Shinohara-Tanaka, K., Ikeda, K., Yamamoto, H., Yamamoto, T., Lesch, K. P., Murphy, D. L., Hall, F. S., Uhl, G. R., and Sora, I. (2004). Regional differences in extracellular dopamine and serotonin assessed by *in vivo* microdialysis in mice lacking dopamine and/or serotonin transporters. *Neuropsychopharmacology* **29,** 1790–1799.

Sora, I., Wichems, C., Takahashi, N., Li, X. F., Zeng, Z., Revay, R., Lesch, K. P., Murphy, D. L., and Uhl, G. R. (1998). Cocaine reward models: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. *Proc. Natl. Acad. Sci. USA* **95,** 7699–7704.

Sora, I., Hall, F. S., Andrews, A. M., Itokawa, M., Li, X. F., Wei, H. B., Wichems, C., Lesch, K. P., Murphy, D. L., and Uhl, G. R. (2001). Molecular mechanisms of cocaine reward: Combined dopamine and serotonin transporter knockouts eliminate cocaine place preference. *Proc. Natl. Acad. Sci. USA* **98,** 5300–5305.

Sulzer, D., Sonders, M. S., Poulsen, N. W., and Galli, A. (2005). Mechanisms of neurotransmitter release by amphetamines: A review. *Prog. Neurobiol.* **75,** 406–433.

Uhl, G. R., Hall, F. S., and Sora, I. (2002). Cocaine, reward, movement and monoamine transporters. *Mol. Psychiatry* **7,** 21–26.

White, F. J., and Kalivas, P. W. (1998). Neuroadaptations involved in amphetamine and cocaine addiction. *Drug Alcohol Depend.* **51,** 141–153.

Ann. N.Y. Acad. Sci. ISSN 0077-8923

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs

Ichiro Sora,[1] BingJin Li,[1] Moe Igari,[1] F. Scott Hall,[2] and Kazutaka Ikeda[3]

[1]Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan. [2]Molecular Neurobiology Branch, National Institute on Drug Abuse, Baltimore, Maryland, USA. [3]Division of Psychobiology, Tokyo Institute of Psychiatry, Tokyo, Japan

Address for correspondence: Ichiro Sora, Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan. Voice: +81-22-717-8593; fax: +81-22-717-7809. isora@mail.tains.tohoku.ac.jp

The first transgenic models used to study addiction were based upon *a priori* assumptions about the importance of particular genes in addiction, including the main target molecules of morphine, amphetamine, and cocaine. This consequently emphasized the importance of monoamine transporters, opioid receptors, and monoamine receptors in addiction. Although the effects of opiates were largely eliminated by μ opioid receptor gene knockout, the case for psychostimulants was much more complex. Research using transgenic models supported the idea of a polygenic basis for psychostimulant effects and has associated particular genes with different behavioral consequences of psychostimulants. Phenotypic analysis of transgenic mice, especially gene knockout mice, has been instrumental in identifying the role of specific molecular targets of addictive drugs in their actions. In this article, we summarize studies that have provided insight into the polygenic determination of drug addiction phenotypes in ways that are not possible with other methods, emphasizing research into the effects of psychostimulant drugs in gene knockouts of the monoamine transporters and monoamine receptors.

Keywords: transgenic; knockout; psychostimulant; amphetamine; cocaine

Introduction

In recent years important advances have been made in developing new animal models to help identify the mechanisms of action of psychostimulant drugs underlying their behavioral and physiological effects, including the abuse liability of these drugs and other adverse consequences, in particular the toxicity and lethality associated with the use of psychostimulant drugs. Genetic mouse models are being used to identify genes that may predict risk for the development of drug abuse and addiction or to investigate under more controlled circumstances the consequence of direct manipulation of particular genes implicated in addiction from human genetic studies. Genetic mouse models have been used for estimating genetic correlations between drug-related traits[1,4] and for studying the roles of specific genes in addiction relevant behavioral and physiological traits.[5,6] Progress in this area of research has profound implications for the improved understanding and treatment of drug addiction. At this time there is a large literature on responses to psychostimulants in gene mutant mice. The largest body of literature on the genetics associated with psychostimulant-related behavioral effects has focused on drug reward and drug conditioning, including conditioned place preference (CPP) and self-administration. This work has emphasized primarily the acute rewarding effects of psychostimulants, or early stages of drug taking. Several other areas have been less well examined or, sometimes, not examined at all. There is a need for more investigation of the genetic determinants of sensitivity to psychostimulant-induced neurotoxicity and other adverse effects. Similarly, there is a great deal of work to be done in the quest for genes that influence the development and acceleration of psychostimulant dependence and phenotypes that may be associated with later stages of the addictive process, including extinction, reinstatement, reconsolidation, habit formation, and many other mnemonic aspects of responses to addictive drugs.

So saying, transgenic models have contributed greatly to our understanding of the mechanisms underlying the actions of psychostimulant drugs. One surprising outcome of these studies has been the polygenic basis of these effects and the degree to which substantial perturbations from gene deletions may alter the normal mechanism of action of particular drugs. Thus, animals will show the same underlying behavioral phenotype, sometimes largely unaltered from the wild-type (WT) condition, but its underlying basis appears to be quite different. Several examples of this type of finding are discussed in the sections that follow, raising the important question of whether similarly large differences in underlying mechanisms exist in humans as are observed in some of these types of models.

Monoamine transporter knockouts

Psychostimulant drugs increase extracellular levels of monoamines by blocking the neuronal plasma membrane transporters (reuptake inhibitors) or by blocking the vesicular transporter (releasers). Increased extracellular dopamine (DA) levels in mesocorticolimbic DA systems have been postulated to mediate the rewarding effects of cocaine,[7] as well as other psychostimulants. The heritability of drug abuse and dependence is relatively high for psychostimulants,[8] indicating that genetic differences that determine the extent of DA release may be important determinants of addiction liability, as well as other effects of acute and chronic psychostimulant exposure. For example, we have recently shown that the number of repeat alleles of the DA transporter (DAT) gene is associated with the risk for methamphetamine (METH) psychosis.[9] This study demonstrated that the presence of nine or fewer repeat alleles of the variable number of tandem repeats in the 3′ untranslated region of DAT is a strong risk factor for a poorer prognosis of METH psychosis. Studies in transgenic mice, particularly knockout (KO) mice in which one or both of the gene alleles are deleted or inactivated, have contributed a great deal to our understanding of the mechanisms underlying psychostimulant actions. This has been particularly useful in the study of psychostimulants because they generally bind to multiple transporters and thereby affect the function of multiple monoamine systems.

Cocaine

Initial transgenic studies into the molecular mechanisms of the effects of psychostimulants, using mice lacking the monoamine transporters, were substantially influenced by the previous pharmacological literature. Prior to the development of these transgenic models, the rewarding effects of cocaine were found to be best correlated with DAT blockade on the basis of structure–activity relationships of transporter-blocking compounds with different potencies at DAT, the serotonin transporter (SERT), and the norepinephrine transporter (NET).[7] As can be seen in Table 1, most studies have concentrated on the rewarding and locomotor stimulant effects of cocaine, with much less work examining other psychostimulant effects.

DAT, SERT, and NET gene KO mice

In contrast to the hypothesis stated in the preceding paragraph, initial data in DAT KO mice demonstrated intact cocaine reward in the CPP paradigm[3] and in an initial self-administration study.[10] Hence DAT KO mice retained the ability to acquire and maintain cocaine self-administration, as well as cocaine-conditioned behavior, in ways that were not substantially different from WT mice. These data therefore indicated that the reinforcing effects of cocaine could be mediated via DAT-independent mechanisms. This is not to say that these data indicated that there was no involvement of DA in cocaine reward. In the Sora *et al.*[3] study, cocaine CPP was observed at both doses tested in WT mice, but only the higher dose produced a significant CPP in DAT KO mice. However, with the largely intact effects of cocaine in these studies, the logical next step was to examine whether other cocaine targets (e.g., SERT and NET) were involved. Further work continued to emphasize that the consequences of cocaine administration were determined by multiple interacting systems. In support of this conclusion, drawn in part from studies of mice in which multiple genes were manipulated with transgenic methods, genetic background was also found to affect the consequence of single-gene KOs. Thus, cocaine CPP was more substantially reduced in congenic DAT KO mice on either a C57BL/6[11,12] or DBA/2J[12] background, which would suggest that the expression of other genes in particular genetic backgrounds affected the consequence of the gene KO. Obviously

Table 1. Cocaine responses in monoamine transporter transgenic mice

Citation	Gene	Micro-dialysis	Loco-motion	Sensiti-zation	CPP	Self-administration	PPI	Adverse effects
Giros, B. *et al.* 1996	DAT KO		Eliminated					
Sora, I. *et al.* 1998	DAT KO		Eliminated		CPP at highest dose only			
Rocha, B.A. *et al.* 1998	DAT KO					Unaffected		
Gainetdinov, R.R. *et al.* 1999	DAT KO		Cocaine decreased locomo-tion					
Carboni, E. *et al.* 2001	DAT KO	Increased DA in NAc						
Ralph, R.J. *et al.* 2001	DAT KO						Reversed PPI deficit	
Mead, A.N. *et al.* 2002	DAT KO			Eliminated				
Morice, E. *et al.* 2004	DAT KO		Eliminated		Substantially decreased			
Shen, H.W. *et al.* 2004	DAT KO	Increased DA in striatum and PFc, but not NAc						
Mateo, Y. *et al.* 2004	DAT KO	Increased DA in NAc and striatum						
Barr, A.M. *et al.* 2004	DAT KO						Reversed PPI deficit	
Medvedev, I.O. *et al.* 2005	DAT KO		Eliminated		Substantially decreased			
Yamashita, M. *et al.* 2006	DAT KO						Reversed PPI deficit	
Thomsen, M. *et al.* 2009	DAT KO					Substantially decreased		
Hall, F.S. *et al.* 2009	DAT KO		Conditioned locomo-tion was eliminated					
Zhuang, X. *et al.* 2001; Tilley, M.R. *et al.* 2007	DAT KD		Increased locomotor by low doses of cocaine		Unaffected			

Continued

Table 1. *Continued*

Citation	Gene	Micro-dialysis	Loco-motion	Sensiti-zation	CPP	Self-administration	PPI	Adverse effects
Chen, R. *et al.* 2006; Tilley, M.R. *et al.* 2009; Thomsen, M. *et al.* 2009	DAT CI	Failed to increase DA in NAc	Decreased under non-habituated conditions		Eliminated	Eliminated		
Hnasko, T.S. *et al.* 2007	DD TG				Unaffected			
Sora, I. *et al.* 2001	DAT/SERT KO				Eliminated			
Xu, F. *et al.* 2000	NET KO				Increased			
Kaminski, R.M. *et al.* 2005	NET KO							Reduced seizures
Hall, F.S. *et al.* 2002	NET/SERT KO				Increased			
Sora, I. *et al.* 2001	SERT KO				Increased			
Homberg, J.R. *et al.* 2008	SERT KO		Increased		Increased	Increased		
Wang, Y.M. *et al.* 1997	VMAT2 KO		Increased	Eliminated				

PFc: prefrontal cortex, NAc: nucleus accumbens.

few species comparisons are available for transgenic models, but in one rare case much more consistent effects of SERT KO are observed in rats, in which cocaine locomotion, cocaine CPP, and cocaine self-administration are all increased,[13] compared to levels in mice, as discussed in the following.

In any case, the observation of intact reward under at least some conditions in DAT KO mice suggested the necessity of examination of the role of the other main targets of cocaine in cocaine reward. Because manipulations of serotonin (5-HT) systems can modulate the rewarding effects of both cocaine and amphetamine (AMPH),[14,15] 5-HT was initially considered to be the most likely candidate. However, cocaine CPP was not reduced in SERT KO mice,[16] nor in NET KO mice[17]; indeed, the opposite was found: both SERT KO and NET KO mice exhibited increased rewarding effects of cocaine, effects that were even more pronounced in mice with deletion of both genes.[18] The failure of any single monoamine transporter gene KO strain to eliminate cocaine reinforcement and reward thus left open several possible roles for these transporters in cocaine reward in WT and DAT KO mice,[5] including the possibility of substantial compensatory changes and the possibility that, under normal circumstances in WT mice, multiple monoamine systems are involved in the rewarding effects of cocaine. Supporting the compensation hypothesis, SERT blockade with fluoxetine or selective NET blockade with nisoxetine was shown to produce rewarding effects in DAT KO mice, effects that are not seen in WT mice.[18] Thus, absence of DAT throughout development could produce changes in other monoamine systems that alter the reinforcing effects of SERT and NET blockade in DAT KO mice. This does not necessarily mean that SERT does not, or can not, have a role in the rewarding effects of cocaine in WT mice. Indeed, both of the foregoing hypotheses are consistent with our findings that combined deletion of DAT and SERT eliminate cocaine CPP.[16]

In contrast to findings in the CPP paradigm, our line of DAT KO mice failed to consistently self-administer cocaine.[19] This finding was in apparent contrast to a previous report that a different line of DAT KO mice did self-administer cocaine.[10] Several factors might have contributed to the differences between these studies. The initial Rocha *et al.*[10] study

examined self-administration under only a few basic circumstances and those authors suggested that although DAT KO mice could self-administer cocaine, a more detailed analysis would be needed to determine whether other differences did exist. The Thomsen *et al.*[19] study was much more detailed and could be summarized thus: DAT KO mice can self-administer cocaine, but the rewarding effects of cocaine are substantially reduced so that even those mice that do learn to self-administer cocaine under initial conditions fail to do so under more demanding conditions, such as increasing the amount of work required to receive cocaine reinforcement by increasing the fixed ratio schedule or under a progressive ratio. This finding is also consistent with our DAT/SERT double-KO study,[16] which found that although combined DAT/SERT deletion eliminated cocaine CPP, the contribution of DAT and SERT was not equal; cocaine CPP was impaired in $DAT^{-/-}SERT^{+/-}$ mice, but not in $DAT^{+/-}$ $SERT^{-/-}$ mice, suggesting a greater overall role of DAT than of SERT. However, there may be contributions of other factors to the differences between the two lines of DAT KO mice in self-administration studies. For instance, cocaine increased extracellular DA levels in the caudate putamen and prefrontal cortex, but not the nucleus accumbens in our line of DAT KO mice,[20] but in the other line of DAT KO mice cocaine and AMPH increased extracellular DA in the medial part of the nucleus accumbens.[21] It is difficult to say why these differences occurred on the basis of our present knowledge, although one is tempted to speculate that differences in genetic background might contribute, as has been shown to be the case for μ opioid receptor KO mice.[22]

DAT-overexpressing transgenic mice

Another DAT transgenic strain that produced overexpression of DAT emphasizes the importance of DAT in the rewarding effects of cocaine.[23] These mice demonstrated increased cocaine CPP, but interestingly, there was no effect on cocaine-induced locomotion.

DAT knockdown mice

As discussed previously, there are substantial compensatory changes in DAT KO mice (see Gainetdinov and Caron[24] for review). Another line has been created in which DAT expression is reduced by 90% (termed DAT knockdown [KD]), which ameliorated some of the effects of complete DAT KO, although DAT KD mice were still hyperactive, had reduced DA clearance, and had slightly elevated extracellular DA levels.[25] The DAT KD mutant line was produced by insertion of a targeting sequence into the promoter region of the DAT gene, resulting in a reduction in DAT expression to approximately 10% of WT levels. Nonetheless, all these changes were less pronounced than those seen in complete DAT KO mice. In contrast to what is observed in complete DAT KO mice, DAT KD mice show enhanced locomotor stimulant effects of low doses of cocaine, whereas there were no effects on cocaine CPP.[26]

Vesicular monoamine transporter 2 KO mice

Vesicular monoamine transporter 2 (VMAT2) is a proton-dependent transporter that accumulates monoamine neurotransmitters, including DA, 5-HT, norepinephrine, and histamine, from neuronal cytoplasm into synaptic vesicles. Normal vesicular monoamine release through calcium-dependent vesicle fusion with presynaptic membranes thus depends on normal function of VMAT2. Homozygous VMAT2 deletion is lethal within a few days postnatal, but heterozygous VMAT2 deletion results in a substantial reduction in presynaptic stores of neurotransmitters.[27] Surprisingly, given these results, $VMAT2^{+/-}$ mice have increased locomotor responses to acute cocaine[27] but do not exhibit cocaine sensitization with repeated administration, which was interpreted as reflecting a "presensitized" state. No changes in DAT function were observed in $VMAT2^{+/-}$ mice *in vitro*, although substantial changes were observed in $VMAT2^{-/-}$mice *in vitro*[28] and *ex vivo*,[2] but high-affinity DA D_2 receptors are elevated in $VMAT2^{+/-}$ mice,[29] as is seen in sensitized animals.[30]

DAT cocaine-insensitive mice

Although the DAT KO mouse has been useful in the study of psychostimulants, because of the changes that appear to occur in these mice an important recent development has been a transgenic manipulation that does not produce such dramatic changes in dopaminergic function. The amino acid residues in transmembrane domain 2 of mouse DAT are important for high-affinity cocaine binding. Another transgenic line has been created in which the mutations in these residues have been engineered, creating a DAT protein that is 80-fold less

sensitive to cocaine inhibition (termed DAT cocaine insensitive [CI]) but relatively normal DA reuptake, and consequently fewer compensatory changes than those observed in DAT KO or DAT KD mice.[31] Although there were small baseline differences in DA uptake kinetics, cocaine failed to increase extracellular DA levels or modify DA cell firing in DAT CI mice.[31] Increased locomotion in a novel environment was observed in these mice and, as typical of DAT KO mice under some circumstances, cocaine reduced locomotion in DAT CI mice.[31] However, several cocaine effects were eliminated in this transgenic strain, including cocaine CPP,[31,32] cocaine self-administration,[33] and cocaine-induced stereotypical behavior,[34] indicating the primacy of DAT in many cocaine actions, including cocaine reward. Because cocaine did not elevate extracellular DA in the nucleus accumbens of the DAT CI mouse line,[31] these findings seem to support the notion that cocaine-induced increases in extracellular DA in the nucleus accumbens are critical for cocaine reward and that in WT mice DAT inhibition is the primary mechanism underlying the rewarding effects of cocaine.

DAT/SERT double-KO mice

Some of the preceding studies suggest that nondopaminergic mechanisms are (or can be) involved in the rewarding effects of cocaine. As mentioned previously, cocaine CPP is eliminated in double-KO mice with no DAT gene copies and either no or one copy of the SERT gene.[16] These results in DAT/SERT double-KO mice suggest that the blockade of DAT and SERT are both involved in cocaine reward,[35] at least under some circumstances, although they do not necessarily indicate that DA does not have a primary role. Indeed, in distinct contrast to WT mice, pharmacological inhibition of SERT increased extracellular DA in the nucleus accumbens[36] and caudate putamen[20] of DAT KO mice to a similar extent as cocaine, which was suggested to result from adaptations in 5-HT regulation of dopaminergic neuronal activity in the ventral tegmental area of these mutant mice. Several pieces of evidence support this hypothesis. Local-infusion cocaine, fluoxetine, or nisoxetine into the dorsal or ventral striatum do not increase extracellular DA levels,[20,36] but local injections of cocaine or fluoxetine in the ventral tegmental area increase extracellular DA concentrations in the nucleus accumbens.[36] This could certainly be the basis for the novel CPP induced by fluoxetine in these mice that was discussed earlier. These studies indicate that there are interactions between DAT and SERT that are important determinants of the rewarding effect of psychostimulant drugs, such as cocaine, under at least some conditions.

Dopamine-deficient mice

Supporting these conclusions, another study has shown similarly important DA–5-HT interactions in another transgenic model, the DA-deficient (DD) mouse model in which tyrosine hydroxylase, the rate-limiting enzyme for catecholamine biosynthesis, has been inactivated selectively in DA neurons but not other catecholaminergic neurons.[37] In these mice inhibition of SERT with fluoxetine produced a CPP,[37] just as it did in DAT KO mice, indicating adaptive changes in 5-HT systems under these even more extreme circumstances. In both the DAT KO and DD models SERT appears to be an important mediator of cocaine reward, but these effects are still likely to involve DA. Both cocaine and fluoxetine CPP were blocked by inhibition of DA cell firing by the DA D_2 receptor agonist quinpirole in DD mice.[37] Those authors suggested that in DD mice cocaine increases 5-HT levels, activating DA neurons, which are still found in DD mice,[38] releasing another (unknown) neurotransmitter, perhaps one of the neuropeptides colocalized with DA. They further suggested that the proposed paradoxical excitatory effects of 5-HT in DD mice result from the hyperdopaminergic state produced by the daily L-dopa administration without which these mice would die, and which may be similar to the hyperdopaminergic state characterized in DAT KO mice.

Behavioral sensitization

The studies discussed in the foregoing sections addressed drug reward primarily as assessed by the CPP and self-administration paradigms. Other models thought to address important aspects of addiction have been less well-studied in monoamine transporter KO mice, including behavioral sensitization. Behavioral sensitization is a phenomenon whereby repeated intermittent exposure to psychostimulant drugs elicits progressive enhancement of behavioral responses, which persists for extended periods after withdrawal from the drug.[39] It is most common to examine sensitization of the locomotor

stimulant effects of drugs, such as cocaine, which are thought to reflect the underlying alterations in neuronal plasticity associated with changes in mesolimbic DA functioning that mediate drug-seeking behavior.[40,41] DAT KO mice are profoundly hyperactive in a novel environment but do not demonstrate acute locomotor stimulant effects of cocaine,[3,42] at least when injected after a period of habituation to the environment. This is also true of C57BL/6J and DBA/2J congenic DAT KO lines.[12] Under these conditions $DAT^{+/-}$ mice show normal baseline locomotion and normal locomotor stimulant effects of cocaine. By contrast, when tested under nonhabituated conditions decreased locomotion is observed after administration of cocaine in $DAT^{-/-}$mice.[43] Habituation appears to be a critical factor in determining these effects; in animals that were substantially habituated prior to drug administration both the acute locomotor effects of cocaine and sensitization of those effects were almost completely eliminated in both $DAT^{+/-}$ and $DAT^{-/-}$ mice.[44] In the same experiment normal acute locomotor effects and sensitization were observed in NET KO mice. One of the more important implications of this later study was that, at least under some conditions, heterozygous DAT KO is sufficient to reduce the locomotor stimulant effects of cocaine. This is important because the heterozygous condition, which produces a 50% reduction in DAT levels in comparison to WT mice, much more closely models the range of variance in DAT levels observed in humans[45] than the homozygous condition.

Although consistent with some other results, the study by Mead *et al.*[44] is difficult to compare with much of the literature on locomotor sensitization because it involved extended periods of habituation (12 h) and an intravenous route of administration. Sensitization involves two primary components, a context-dependent component (e.g., conditioning) and a context-independent component resulting from adaptations to repeated drug exposure that occur even if given in a context in which limited learning about the drug occurs, such as a familiar home cage environment. Such an extended period of habituation as was used in the Mead *et al.*[44] study is likely to eliminate most context dependent aspects of sensitization. Another way to approach sensitization is to specifically examine the ability of the environment, after repeated exposure to the drug, to elicit locomotion after reexposure to the environment without the drug, which is termed "conditioned locomotion." We recently examined conditioned locomotion in DAT KO, SERT KO, and NET KO mice.[46] This study found that conditioned locomotion was eliminated in DAT KO mice, but not SERT KO or NET KO mice, although small diminutions in the conditioned responses were observed in each case. In addition, repeated exposure to cocaine, either during the conditioning trials or in the home cage, resulted in sensitization of locomotor responses in the testing environment in DAT KO mice. This effect occurred in DAT KO mice that did not show acute locomotor stimulant responses to cocaine, as well as in animals given saline before locomotor testing but that received cocaine later in the home cage. Thus, even though the conditioned component was eliminated, long-term adaptations to repeated cocaine exposure were observed in DAT KO mice that may have been stronger than those observed in WT mice.

Prepulse inhibition

The hyperdopaminergia of DAT KO mice, judged in terms of extracellular DA levels in the striatum or DA-associated behaviors, such as hyperactivity, have led to the suggestion that DAT KO mice can be used as animal models of schizophrenia[47] and attention-deficit/hyperactivity disorder (AD/HD).[48] There is evidence to support both views to a certain extent. The paradoxical inhibitory effects of several psychomotor stimulants, including cocaine, on the profound locomotor hyperactivity observed in DAT KO mice have already been mentioned.[43] DAT KO mice also have deficits in prepulse inhibition (PPI) of the acoustic startle reflex, a model of sensorimotor gating,[49,50] which are also reversed by treatment with several psychostimulants, including cocaine.[51] PPI deficits in DAT KO mice can also be reversed by D_2 antagonists[50] or 5-HT_{2A} antagonists,[49] further supporting the idea of interactions between DA and 5-HT systems being fundamentally important in these mice. However, the underlying deficit in DAT KO mice is likely to involve alterations in the balance between ventral striatal and prefrontocortical activity. In part, this results from an oddity of DA function in the prefrontal cortex whereby uptake is normally mediated by NET rather than DAT.[52,53] One consequence of this situation is that in the absence of DAT in DAT KO mice

there are profound alterations in extracellular DA concentrations in the ventral striatum, whereas the prefrontal cortex remains substantially unaffected,[20] thereby potentially altering the balance of activity between the prefrontal cortex and the ventral striatum. This would appear to have dramatic effects on responses to cocaine, which impairs PPI in WT mice but normalizes PPI in DAT KO mice.[51] This study went on to show that, consistent with the previous argument regarding the normal mechanisms of DA reuptake in the prefrontal cortex, the selective NET blocker nisoxetine, normalized PPI in DAT KO mice as well. By contrast, the selective SERT blocker citalopram was without effect, although fluoxetine did reverse DAT KO impairments in PPI. This difference between the effects of citalopram and fluoxetine was suggested to potentially derive from different affinities of fluoxetine and citalopram for NET and 5-HT_{2A} receptors, both of which reversed DAT KO impairments in PPI as discussed in the foregoing text.

Adverse effects of cocaine

Adverse effects of cocaine are observed in humans, including lethality related to cardiac events[54] and seizures.[55] The mechanisms underlying the toxic and lethal effects of cocaine have not been extensively examined using transgenic models, however. With the previous discussion, and the complexity of genetic effects involved in other cocaine actions, it would be important to understand the mechanisms underlying these adverse effects. In the only known such study to date, cocaine-induced seizures were substantially reduced in NET KO mice,[56] although this did not appear to be solely the result of prevention of cocaine actions at NET, because the sensitivity to other seizure-inducing drugs, which do not presumably act at NET, were also reduced.

Amphetamines

It is important to consider separately the effects of different psychostimulant drugs because they have different mechanisms of action, despite many similarities. AMPH and METH are prototypical psychostimulant drugs that induce enhanced arousal and euphoria acutely, and psychosis and addiction chronically, but their mechanisms are quite different from those of cocaine. None of the AMPH are terribly selective in their binding affinities for the three monoamine transporters, although both AMPH and METH are less potent at binding SERT, whereas methylenedioxymethamphetamine (MDMA) has a slightly higher affinity for SERT than for DAT.[57,58] AMPH produce increases in extracellular DA that are dependent on reverse transport via DAT[59] and have similar actions via the other plasma membrane monoamine transporters.[58] This involves cytosolic accumulation of monoamines after inhibition of VMAT2.[60] Because of these mechanisms of action gene KOs of the monoamine transporters have been used to investigate the pharmacological mechanisms underlying the actions of psychostimulants.[2,3,27,42] However, homozygous deletion of the VMAT2 gene was lethal within a short time after birth.[2,61] Consequently, most studies of VMAT2 KO mice have been done in heterozygous KO mice, although another VMAT2 mutant exists that produces a 95% reduction in VMAT2 levels in the homozygous condition and is viable.[62] As mentioned previously, gene KO of monoamine transporters produces substantial changes in baseline neurotransmission. For example, homozygous deletion of the DAT gene produces five- to 10-fold increases in extracellular DA concentrations in the striatum as measured by *in vivo* microdialysis,[20,63] whereas heterozygous deletion of DAT was not found to increase extracellular DA[20] or to produce a more modest twofold elevation of DA in the striatum.[63] Thus, transgenic studies in these KO strains must be interpreted in the context of these baseline alterations.

As can be seen in Table 2, most studies have concentrated on the rewarding and locomotor stimulant effects of AMPH, with much less work examining other psychostimulant effects and less examination of other AMPH compounds.

DAT KO mice

Study of DAT KO mice has demonstrated that the rewarding effect of AMPH is not abolished in the CPP paradigm after deletion of the DAT gene.[64] Interestingly, extinction was substantially reduced in DAT KO mice in this study so that they demonstrated persistent CPP over an extended period (40 days), whereas WT mice showed preference only on the first day of testing. Because AMPH can not access dopaminergic terminals via DAT in these mice, it must be presumed that the rewarding effects of AMPH, like cocaine, are either normally dependent

Table 2. Cocaine responses in monoamine receptor transgenic mice

Citation	Gene	Micro-dialysis	Loco-motion	Sensiti-zation	CPP	Self-administration	PPI	Adverse effects
Xu, M. *et al.* 1994	D_1 KO		Decreased					
Miner, L.L. *et al.* 1995	D_1 KO				Unaffected			
Xu, M. *et al.* 2000	D_1 KO		Eliminated					
Caine, S.B. *et al.* 2007	D_1 KO					Eliminated		
Karlsson, R.M. *et al.* 2008	D_1 KO			Eliminated				
Doherty, J.M. *et al.* 2008	D_1 KO						Eliminated cocaine-induced impair-ments	
Chausmer, A.L. *et al.* 2002	D_2 KO		Unaffected					
Rouge-Pont, F. *et al.* 2002	D_2 KO	Increased DA release						
Caine, S.B. *et al.* 2002	D_2 KO					Increased		
Welter, M. *et al.* 2007	D_2 KO		Decreased		Slight reduction			
Doherty, J.M. *et al.* 2008	D_2 KO						Partially elimi-nated cocaine-induced impair-ments	
Xu, M. *et al.* 1997	D_3 KO		Increased		Increased			
Carta, A.R., C.R. Gerfen & H. Steiner. 2000	D_3 KO		Decreased	Eliminated				
Katz, J.L. *et al.* 2003; Rubinstein, M. *et al.* 1997	D_4 KO		Increased					
Elliot, E.E., D.R. Sibley & J.L. Katz. 2003	D_5 KO		Decreased					
Karlsson, R.M. *et al.* 2008	D_5 KO		Unaffected	Decreased	Unaffected			
Doherty, J.M. *et al.* 2008	D_3 KO						Increased cocaine-induced impair-ments	

Continued

Table 2. *Continued*

Citation	Gene	Micro-dialysis	Loco-motion	Sensiti-zation	CPP	Self-administration	PPI	Adverse effects
Karasinska, J.M. *et al.* 2005	D_1/D_3 KO		Decreased		Decreased			
Rocha, B.A. *et al.* 1997	5-HT_{1B} KO					Increased		
Belzung, C. *et al.* 2000	5-HT_{1B} KO				Unaffected			
Shippenberg, T.S., R. Hen & M. He. 2000	5-HT_{1B} KO	Increased DA release				Increased		
Salomon, L. *et al.* 2007	5-HT_{2A} KO		Increased	Unaffected				
Rocha, B.A. *et al.* 2002	5-HT_{2C} KO							
Allan, A.M. *et al.* 2001	5-HT_3 over-expression				Decreased			
Witkin, J.M. *et al.* 2007	5-HT_7 KO							Increased cocaine-induced seizures and lethality
Schank, J.R. *et al.* 2006	DBH KO		Increased		Preference at 5 mg/kg, aversion at 20 mg/kg			
Jasmin, L., M. Narasaiah & D. Tien. 2006	DBH KO				Eliminated			
Gaval-Cruz, M. *et al.* 2008	DBH KO							No effect on cocaine induced seizures
Drouin, C. *et al.* 2002	α_{1b} KO		Decreased	Decreased				

on a combination of monoaminergic effects or in the absence of DAT other monoaminergic mechanisms can compensate for the absence of DAT. Again, like the circumstance with cocaine, this is not to say that DA has no role, even without DAT. Systemic AMPH still increases extracellular DA in the nucleus accumbens without DAT,[21,64] although local striatal infusion does not.[64] Furthermore, this study also demonstrated that AMPH would reduce DA cell firing in WT mice but not in DAT KO mice. This effect is probably due to reduced autoreceptor function in DAT KO mice,[65] which reveals an underlying non–DAT-mediated stimulatory effect that can be observed when autoreceptor feedback is impaired.[66] With these data, as well as the data discussed earlier for cocaine, it would seem likely that serotonergic mechanisms are involved in AMPH CPP in DAT KO mice. Consistent with this hypothesis, AMPH-induced CPP was abolished by pretreatment with a 5-HT_{1A} receptor antagonist in DAT KO mice, even though the drug did not change AMPH place preference in WT mice,[64] again suggesting that the basis

of psychostimulant reward is somewhat different in mice that have experienced a lifelong deletion of the DAT gene. These results indicate that other mechanisms, most likely involving 5-HT, may not play a major role in the rewarding properties of AMPH in WT mice, although the extent of this interaction may be influenced by genetic background, as mentioned earlier, and will require further clarification.

By contrast, the acute locomotor response to AMPH was abolished in these mice under nonhabituated conditions; indeed, reductions in locomotion are often observed in DAT KO mice after administration of AMPH,[43,67] as was the case for cocaine, so that these effects in DAT KO mice are likely to be mediated by SERT, because fluoxetine produced a similar results in these mice.[43,67] Similar changes in response to AMPH are also observed in DAT KD mice.[25] NET may also have a role in these effects because NET KO has been found to increase the locomotor stimulant effects of AMPH.[17] As discussed in the preceding text, locomotor hyperactivity in DAT KO mice has been considered an animal model of AD/HD, an assertion that these "paradoxical" effects of psychostimulants support. Furthermore, these effects are associated with opposite effects of AMPH on postsynaptic signal transduction.[68]

DAT-overexpressing transgenic mice

As was demonstrated for cocaine,[23] overexpression of DAT has been shown to affect responses to AMPH in a separate transgenic line,[69] including increased AMPH CPP, AMPH-induced locomotion, and striatal DA efflux. Interestingly, there were no changes in the locomotor responses to several selective and nonselective DA reuptake blockers in that study, which may indicate that these effects are mediated by other transporters.

VMAT2 KO mice

Although the plasma membrane transporters for the monoamines may be of considerable importance for the actions of AMPH, the ultimate site of action is VMAT2. Gene KO of VMAT2 (heterozygous) has been reported to reduce AMPH CPP.[2] This result is surprising given the finding that VMAT2 KO produces a slight increase in the locomotor stimulant effects of AMPH.[2,27] Because of the apparent importance of both DAT and VMAT2 for the actions of AMPH and METH, we recently examined locomotor activity and sensitization in heterozygous DAT KO mice, heterozygous VMAT2 KO mice, double-heterozygous DAT/VMAT2 KO mice, and WT mice, to evaluate the roles of DAT and VMAT2 in METH-induced locomotor behavior and sensitization.[70] The acute locomotor stimulant effects of METH administration were attenuated in heterozygous DAT KO mice, whereas they were enhanced in VMAT$^{+/-}$ mice; each of these findings is consistent with previous observations with AMPH[2,27,43,67] (by contrast, SERT KO has no effect on AMPH-induced locomotion[71]). The attenuation of the acute effects of METH in DAT KO mice was observed regardless of whether it was combined with heterozygous VMAT2 KO. Although sensitization was observed in all groups, it was substantially attenuated in DAT KO mice, again regardless of whether it was combined with VMAT2 KO. These findings indicate that the heterozygous deletion of DAT produces a major reduction in acute psychostimulant effects of METH, as well as the sensitization of those effects, probably by reducing the ability of METH to enter DA terminals. The mechanism of the VMAT2 effects is less certain. VMAT2 KO reduces both basal and AMPH-stimulated levels of extracellular DA.[27] Thus, these effects may reflect, at least in part, compensatory changes in postsynaptic mechanisms in VMAT2$^{+/-}$ mice, which show increased responses to postsynaptic DA agonists[27] and increased high-affinity DA D_2 receptor function.[29]

Adverse effects of amphetamines

Although addiction is a serious problem for all psychostimulants, neurotoxicity and other adverse consequences of long-term AMPH use is an additional concern, although some AMPH produce more adverse effects than others. METH abuse presents serious health hazards, including irreversible neuronal degeneration, seizures, hyperthermia, and death in humans and experimental animals.[72] METH produces hyperthermia and dopaminergic neurotoxicity in most species examined. Clinical reports and animal studies indicate that lethality from METH closely correlates with hyperthermia, which may be the primary cause of death in cases of overdose. Animal studies suggest that DA receptor activation is crucial for both METH-induced hyperthermia[73] and lethality,[74] although at times there has been an assumption that the METH-induced hyperthermia is 5-HT receptor mediated, as are the

hyperthermic effects of MDMA.[75] In a recent study, we examined hyperthermic and lethal toxic effects of METH in DAT, SERT, and DAT/SERT double-KO mice to elucidate the role of these two transporters in METH-induced hyperthermia and lethality.[76] METH caused significant hyperthermia even in mice with one DAT gene copy and no SERT copies, whereas mice with no DAT copies and one SERT gene copy showed significant but reduced hyperthermia when compared to WT mice after METH treatment. These results demonstrate that METH may exert a hyperthermic effect via DAT, or via SERT, without DAT. Double KO of both the DAT and SERT genes eliminated the hyperthermic effects of METH and revealed a hypothermic response. As might be expected given these findings, DAT gene deletion in mice strikingly increased the 50% lethal dose for METH by 1.7-fold compared to WT mice. However, hyperthermia was not solely responsible for lethality, because the mechanisms mediating hyperthermia and toxicity could be dissociated: DAT KO (SERT WT) mice exhibited hyperthermia but greatly reduced METH lethality, and the lethality was not different from DAT/SERT double-KO mice that had hypothermic responses to METH. These findings indicate that DAT may be a more critical mediator of the adverse events associated with METH overdose than SERT.

As mentioned before, a major concern regarding the widespread illicit use of AMPH and METH is their neurotoxic potential, as revealed in animal studies and as observed clinically. This includes both acute adverse events, as discussed earlier, as well as long-term effects of neuronal toxicity and other changes produces by these drugs. In animal models, METH produces dopaminergic,[77] and to a lesser extent serotonergic,[78] neurotoxicity. The neurotoxic effects of METH on DA neurons are eliminated in DAT KO mice,[79] although the effects of METH on serotonergic neurons are attenuated but still present. The neurotoxic effects of METH are enhanced in VMAT2$^{+/-}$ KO mice,[80,81] as are the neurotoxic effects of MPTP[2,82] and L-dopa.[83] Enhanced neurotoxicity was not observed after subchronic treatment with L-dopa in VMAT2$^{+/-}$ KO mice.[84] Increased dopaminergic toxicity after acute treatments with these agents may reflect a generally diminished capacity of VMAT2 to sequester toxins[85] in VMAT2$^{+/-}$ KO mice, as well as increased accumulation of oxidative metabolites resulting from elevated cytosolic DA concentrations. Although homozygous VMAT2 KO is lethal with a few days postnatally, a study that examined early postnatal ventral midbrain cultures from VMAT2$^{+/+}$, VMAT2$^{+/-}$, and VMAT2$^{-/-}$ mice found that there was an inverse relationship between VMAT2 expression and dopaminergic toxicity.[86]

MDMA

MDMA is another commonly abused AMPH compound that produces positive subjective feelings, produces reward, and is associated with several adverse effects including hyperthermia, lethality, and neurotoxicity.[87] The subjective state induced by MDMA is described as qualitatively different from that of other AMPH and is said to include feelings of openness and empathy.[88] Although many of its behavioral and psychological consequences have been associated with its effects on serotonergic function, MDMA increases DA and norepinephrine function as well.[89] There is evidence that MDMA CPP and self-administration depend on DA systems,[90,91] although its affinity for SERT is higher than its affinity for DAT[58] and it produces greater release of 5-HT than DA.[92] Thus, the dopaminergic effects of MDMA are likely to be indirect consequences of MDMA actions. This idea is supported by the demonstration that deletion of the SERT gene eliminates the acquisition of MDMA self-administration.[93] Some of these effects may be open to other interpretations, however. Part of the effect of SERT KO on operant responding for MDMA appeared to be due to more generalized behavioral or cognitive deficits that delayed the acquisition, and maximal response rate, of operant responding for food and water rewards. Indeed, we observed similar deficits for acquisition of cocaine self-administration in SERT KO mice.[19] However, these more general deficits in operant responding can not fully account for the effects of SERT KO on MDMA self-administration, which was abolished, as were the locomotor stimulant effects of MDMA.[71] Deletion of the SERT gene increases basal levels of 5-HT in diverse brain regions but does not affect basal DA levels.[20,94,95] Although the elevations in extracellular DA produced by MDMA in the nucleus accumbens were unaffected by deletion of the SERT gene, MDMA-induced increases in extracellular 5-HT in the prefrontal cortex were abolished,[93]

as was 5-HT release in the dorsal raphe and consequent inhibition of serotonergic neurons,[96] indicating that changes in 5-HT in SERT KO mice may have the greatest relevance to the behavioral effects of MDMA discussed earlier.

In addition to its abuse potential, MDMA produces long-term changes in serotonergic neurons that have been described as neurotoxic.[92] The nature of MDMA "neurotoxicity" is a matter of debate, and although it has been suggested that this is, strictly speaking, not the case, substantial impairments in serotonergic functioning are observed.[97] Many of the long-term effects of MDMA administration, including dorsal raphe 5-HT_{1A} supersensitivity, decreased hippocampal cell proliferation, and depressive-like behavior, are all eliminated in SERT KO mice, suggesting that SERT is the primary mediator of these adverse effects as well.[96] Of course, one interpretive problem for some of these effects is that SERT KO mice, in some respects, have baseline phenotypes characteristic of WT mice chronically treated with MDMA to begin with. Other genes are important in the neurotoxic effects of MDMA as well. MDMA-induced 5-HT depletion is eliminated in MAO-B KO mice,[98] and even more interesting, in these mice DA depletion is enhanced.

Methylphenidate

Methylphenidate is a nonspecific monoamine reuptake blocker with a greater affinity for NET than cocaine, but a relatively weak affinity for SERT,[99] and the prototypical AD/HD treatment. As with other monoamine blockers, the relative importance of methylphenidate binding to different monoamine transporters for its behavioral effects is a matter of some debate. As discussed, DAT KO produces impairments in PPI that can be ameliorated by cocaine and AMPH. If this is indeed a model of AD/HD, at least in certain respects, then it should be expected that methylphenidate should also ameliorate these attentional deficits. Indeed, methylphenidate was found to ameliorate DAT KO induced PPI deficits[51] and hyperactivity.[43] In WT mice, methylphenidate produces activation of the *c-fos* in diverse brain areas that are not activated in DAT KO mice,[100] whereas DAT KO mice have activation of the *c-fos* in brain areas that are not normally activated in WT mice. This different pattern of *c-fos* activity in WT and DAT KO mice was thought to reflect dopaminergic, versus nondopaminergic, mechanisms of methylphenidate and are consistent with the different behavioral effects of methylphenidate in these mice. The locomotor-decreasing effects of methylphenidate in hyperactive DAT KO mice may also be associated with the opposite effects of AMPH on postsynaptic signal transduction compared to WT mice.[68]

Although some responses to methylphenidate are substantially altered in DAT KO mice, the rewarding effects of methylphenidate in the CPP paradigm are unaffected,[3] similar to the effects of cocaine in these mice. As discussed in a previous section, some of these effects are probably due to neurodevelopmental or compensatory alterations in DAT KO mice, because similar changes are not observed in the DAT CI mouse. The DAT CI mutant mouse has reduced binding of methylphenidate to the DAT,[101] and the rewarding effects of methylphenidate in the CPP paradigm, as well as the locomotor stimulant and stereotypical effects of methylphenidate, were all eliminated in these mice.

Methylphenidate has a low affinity for SERT, although it does bind to both DAT and NET.[99] Thus, those effects not mediated by DAT are likely to be mediated by NET. Gu *et al.*[102] recently identified a mutant mouse with a cocaine-insensitive NET. Interestingly, the triple mutation in this mouse line resulted in a substantial reduction in binding of cocaine, but it had little effect on the affinity for AMPH or methylphenidate and had relatively normal norepinephrine transport.

Monoamine receptor knockouts

With the substantial evidence for the involvement of monoamine transporters in the effects of psychostimulant drugs, it is not surprising that there is also substantial evidence for the involvement of monoaminergic receptors. As for transporters, much of this research has reflected a dopaminergic emphasis (or bias, perhaps), at least initially, both in the pharmacological literature and in transgenic studies. As can be seen in Table 3, most studies have concentrated on the rewarding and locomotor-stimulant effects of cocaine in dopaminergic receptors, with much less work examining other psychostimulant effects and other monoaminergic receptors.

Table 3. Psychostimulant responses in monoamine transporter transgenic mice

Citation	Gene	Drug	Micro-dialysis	Loco-motion	CPP	Self-administration	Adverse effects
Budygin, E.A. *et al.* 2004	DAT KO	AMPH			Unaffected, abolished by 5-HT_{1A} antagonist		
Salahpour, A. *et al.* 2008	DAT over-expression	AMPH	Increased	Increased	Increased		
Spielewoy, C. *et al.* 2001	DAT KO	AMPH		Decreased			
Xu, F. *et al.* 2000	NET KO	AMPH		Increased			
Takahashi, N. *et al.* 1997; Fukushima, S. *et al.* 2007	VMAT2 KO	AMPH, METH		Increased	Decreased		
Numachi, Y. *et al.* 2007	DAT KO	METH					Reduced hyper-thermia
Fumagalli, F. *et al.* 1998	DAT KO	METH					Eliminated neurotoxic effects
Fumagalli, F. *et al.* 1999; Guillot, T.S. *et al.* 2008	VMAT2 KO	METH					Enhanced neurotoxic effects
Trigo, J.M. *et al.* 2007	SERT KO	MDMA	Abolished 5-HT in PFc			Eliminated	
Bengel, D. *et al.* 1998	SERT KO	MDMA		Eliminated			
Renoir, T. *et al.* 2008	SERT KO	MDMA					Decreased hippocampal cell proliferation was eliminated
Sora *et al.* 1998	DAT KO	Methyl-phenidate			Unaffected		
Tilley, M.R. & H.H. Gu. 2008	DAT CI	Methyl-phenidate		Eliminated	Eliminated		

PFc: prefrontal cortex.

Dopamine receptors

The studies of DAT KO mice discussed herein obviously implicate dopaminergic mechanisms in many psychostimulant effects but do not specify which DA systems are involved. Because of the belief of the importance of DA for psychostimulant effects, some of the first gene KO mice made were for dopaminergic receptor genes. Dopaminergic receptors are classified as D_1-like (D_1 and D_5) or D_2-like (D_2, D_3, and D_4) receptors on the basis of sequence homology and pharmacology.[103] DA receptors also have different distributions in the brain.[104–108] This would then indicate that transgenic manipulations of dopaminergic receptors may produce more specific effects on behavior, and the effects of psychostimulants, than monoamine transporter manipulations. However, it may also be possible that there is a greater possibility of compensation by other receptors in the absence of one.

Cocaine

D_1 KO mice. There is substantial pharmacological evidence for the involvement of DA receptors in drug reward, and in the effects of cocaine in particular. Full D_1-like agonists are self-administered by rats,[109] and administration of D_1-like antagonists decreases cocaine self-administration.[110] Of course one problem with many pharmacological agents used to study dopaminergic effects is specificity for DA receptor subtypes, so that the effects mentioned earlier may not be due to actions at D_1 receptors per se. Transgenic techniques thus presented a way to specifically address which DA receptor subtypes may be involved in the rewarding effects of cocaine. D_1 KO mice have been reported to demonstrate normal responses to the rewarding effects of cocaine in the CPP paradigm,[111] although they do show reduced voluntary ethanol consumption,[112] suggesting that deletion of the D_1 receptor does attenuate the reinforcing properties of some drugs. Interestingly, and in a manner somewhat reminiscent of the consequences of deletion of the DAT gene, the locomotor stimulant effects of cocaine, as well as locomotor sensitization, are eliminated in D_1 KO mice.[111,113,114] Indeed, this parallel may go even further, because D_1 KO mice have been reported to have locomotor-decreasing effects of cocaine.[115] Although another study did not observe this, it did observe locomotor-decreasing effects of cocaine in combined D_1–D_3 KO mice, which were hyperactive at baseline.[116] Combined D_1–D_3 KO also reduced cocaine CPP, but only at the lowest dose examined.[116] Despite the observation of normal cocaine CPP in D_1 KO mice, cocaine self-administration is virtually eliminated, most of the subjects not meeting the criteria for acquisition.[117] Again, this situation is similar to that observed in DAT KO mice in a recent study.[19] In WT mice the immediate early genes *c-fos* and *zif268* are activated by cocaine, but this does not occur in D_1 KO mice, and instead there is activation of the expression of the substance P gene.[118] D_1 KO also reversed the effect of cocaine on CREB phosphorylation, producing decreases, rather than increases, in CREB phosphorylation,[116] and a reduction in the number of pCREB immunoreactive cells were observed throughout the striatum in these mice.

D_2 KO mice. On the basis of pharmacological evidence alone, there is perhaps even more evidence for the involvement of the D_2 receptor in the rewarding effects of psychostimulants. Similar to D_1-like DA receptors, D_2-like agonists are self-administered by rats[109] and D_2-like antagonists reduce cocaine reinforcement.[119] However, despite the indications from pharmacological studies, self-administration of low to moderate doses of cocaine is unaffected, whereas self-administration of moderate to high doses of cocaine is actually increased in D_2 KO mice,[119] and D_2 KO produced only a slight reduction in cocaine CPP.[120] Those authors also found a reduction in the ability of cocaine to stimulate production of c-Fos. D_2 KO also does not affect the discriminative stimulus effect of cocaine.[121] Thus, it would appear at the very least that D_2 KO does not produce quite the same effects as D_2 antagonists in WT mice in models of drug reward. Whether this indicates that there are compensatory changes in other DA receptors, or that normally multiple receptors are involved, remains to be determined.

Similarly to the effects discussed in the foregoing section, locomotor stimulant effects of cocaine were largely unaffected in D_2 KO mice, once differences in basal activity were taken into account,[121] although another study did find reduced locomotor-stimulant effects of cocaine,[120] which was accompanied by pronounced stereotypical grooming. DA autoreceptor function was eliminated in D_2 KO mice,[122] but cocaine-mediated DA efflux was only slightly affected in striatal synaptosomes. This

outcome was observed even though DAT clearance rates were reduced by 50%,[123] which seemed to result from a change in activity because the density and affinity of DAT sites were unchanged. In any case, regardless of the mechanism, these changes are associated with substantially increased DA release in response to cocaine as measured by *in vivo* microdialysis in D_2 KO mice, or mice with a selective deletion of the long isoform of the D_2 (D_{2L}) receptor.[124]

D_3, D_4, and D_5 KO mice. There has been less pharmacological evidence of a role for other DA receptor subtypes in the effects of psychostimulants, although certainly some, and perhaps more for the D_3 receptor,[125] because more selective agents have not been available for as long. Thus, examination of genetic deletion of the other DA receptors should be especially illuminating here. Both D_3 KO mice[126] and D_4 KO mice[127,128] have increased locomotor responses to cocaine. By contrast, D_5 KO was reported to produce a reduction in cocaine-stimulated locomotion,[129] although this effect was not found in another study.[114] The basis of the effects in D_3 and D_4 KO mice was suggested to be quite different. D_3 KO mice have increased sensitivity to combined D_1 and D_2 agonists, so it was suggested that the enhanced responses to cocaine in these mice were due to increased D_1/D_2 synergy.[126] In contrast, the effects of D_4 gene deletion were suggested to be mediated by the elimination of inhibitory effects of the D_4 receptor.[116] In either case the mechanisms involved are somewhat speculative. The baseline difference in cocaine responsiveness observed in D_3 KO mice discussed in the preceding section was not large and limited to a low dose. Using a higher dose and testing in the home cage, another study found that D_3 KO mice had reduced locomotor responses to cocaine, although this appeared to be the result of stereotypical head-bobbing behavior.[130] Furthermore, in WT mice repeated cocaine treatment produced locomotor sensitization, but this was not found in D_3 KO mice, which instead showed sensitized stereotypical head bobbing.[130] The increased stereotypy observed in D_3 KO mice is also associated with increased stimulatory effects on *c-fos* and dynorphin gene expression,[130] which were thought to be indicative of enhanced D_1 stimulation in the absence of D_3. In contrast to diminished effects on cocaine locomotion, D_3 KO mice exhibit increased sensitivity to cocaine in the CPP paradigm.[126] Reduced locomotor sensitization was observed in D_5 KO mice,[114] which did not exhibit sensitization under most conditions tested.

Far less work has been done to examine other psychostimulant effects. The potency of cocaine as a discriminative stimulus was enhanced in D_4 KO mice[127] but unaffected by D_5 KO.[129] Cocaine CPP was also normal in these mice.[114] The ability of cocaine to produce conditioned locomotion is not different in D_3 KO mice compared to WT control mice,[131] although those authors found that D_3 agonists did inhibit the behavior, again suggesting compensatory actions of other DA receptors when one is eliminated. The effects of cocaine on PPI appear to involve DA D_1, D_2, and D_3 receptors.[132] D_1 KO eliminated cocaine-induced impairments in PPI, whereas D_2 KO was partially effective. By contrast, D_3 KO produced increases in cocaine-induced impairments in PPI. Finally, DA receptors may also play a role in cocaine-induced toxicity. Although D_3 KO did not affect cocaine-induced convulsions by itself, it did block the protective effects of a D_2/D_3 agonist, whereas D_2 KO was without effect.[133]

Much more work remains to be done here. Many of the effects of psychostimulants that have been identified in DAT KO mice have not been examined in DA receptor KO mice. Furthermore, as for monoamine transporter KOs, it may be necessary to examine multiple receptor KOs where there is no or little effect of single receptor gene KOs.

Amphetamines

As for cocaine, most transgenic work has concentrated on dopaminergic receptor KOs, as can be seen in Table 4. Most studies have concentrated on the rewarding and locomotor-stimulant effects of AMPH, with much less work examining other psychostimulant effects and other AMPH compounds.

D_1 KO mice. There are conflicting reports on the effects of AMPH in D_1 KO mice. An early study found that although initial locomotor responses to AMPH were unaltered in D_1 KO mice, the sensitization of these responses was diminished.[134] Another study found a slight diminution in the acute locomotor-stimulating effects and largely unaltered locomotor sensitization,[17] although one difficulty of interpretation here was high locomotor activity in saline-treated subjects, so that when this is taken into account, it could be considered that they have reduced sensitization. Contrary to these studies,

Table 4. Psychostimulant responses in monoamine receptor transgenic mice

Citation	Gene	Drug	Locomotion	Sensitization	CPP	PPI	Adverse effects: hyperthermia	Adverse effects: lethality
Crawford, C.A. *et al.* 1997	D_1 KO	AMPH	Unaffected	Decreased				
Karper, P.E. *et al.* 2002	D_1 KO	AMPH		Unaffected				
McDougall, S.A. *et al.* 2005	D_1 KO	AMPH	Increased	Increased				
Ralph, R.J. *et al.* 1999	D_2 KO	AMPH				Disrupted AMPH-induced impairments		
Kelly, M.A. *et al.* 2008	D_2 KO	AMPH	Decreased	Unaffected				
Xu, R. *et al.* 2002	D_{2L} KO	AMPH				Unaffected AMPH-induced impairments		
Xu, M. *et al.* 1997	D_3 KO	AMPH	Increased					
Ralph, R.J. *et al.* 1999	D_3 KO	AMPH				Unaffected AMPH-induced impairments		
Ralph, R.J. *et al.* 1999	D_4 KO	AMPH				Unaffected AMPH-induced impairments		
Kruzich, P.J., K.L. Suchland & D.K. Grandy. 2004	D_4 KO	AMPH		Increased				
Kelly, M.A. *et al.* 2008	D_4 KO	AMPH	Increased					
Harrison, S.J. & J.N. Nobrega. 2009	D_5 KO	AMPH		Increased				
Bronsert, M.R. *et al.* 2001	5-HT_{1B} KO	AMPH	Increased	Increased				
Weinshenker, D. *et al.* 2002	DBH KO	AMPH	Increased	Unaffected				
Drouin, C. *et al.* 2002	α_{1b} KO	AMPH	Decreased	Decreased				

Continued

Table 4. *Continued*

Citation	Gene	Drug	Locomotion	Sensitization	CPP	PPI	Adverse effects: hyperthermia	Adverse effects: lethality
Sallinen, J. *et al.* 1998	α_{2c} KO	AMPH	Increased	Increased				
Lahdesmaki, J. *et al.* 2004	α_{2A} KO	AMPH				Increased AMPH-induced impairments		
Ito, M. *et al.* 2008	D_1 KO	METH					Modestly attenuated METH-induced hyperthermia	Substantially attenuated METH-induced lethality
Ito, M. *et al.* 2008	D_2 KO	METH					Eliminated METH-induced hyperthermia	Substantially attenuated METH-induced lethality
Rubinstein, M. *et al.* 1997	D_4 KO	METH	Increased					
Allan, A.M. *et al.* 2001	5-HT_3 overexpression	METH			Decreased			
Risbrough, V.B. *et al.* 2006.	D_1 KO	MDMA	Increased					
Risbrough, V.B. *et al.* 2006.	D_2 KO	MDMA	Decreased					
Risbrough, V.B. *et al.* 2006.	D_3 KO	MDMA	Unaffected					
Dulawa, S.C. *et al.* 1998, 2000	5-HT_{1B} KO	MDMA				Increased		
Scearce-Levie, K., S.S. Viswanathan & R. Hen. 1999	5-HT_{1B} KO	MDMA	Decreased			Increased		
Bexis, S. & J.R. Docherty. 2005	α_{2A} KO	MDMA					Biphasic response, hypothermia followed by hyperthermia	

another study found generally increased responses to AMPH after chronic treatment in D_1 KO mice, including increased context-dependent sensitization, context-independent sensitization, and conditioned locomotion.[135] Yet another study found no differences in sensitization in D_1 KO mice.[136] It is difficult to say why these different results have been obtained.

D_2 KO mice. One complication of the study of D_2 KO mice is that the D_2 receptor is expressed both presynaptically and postsynaptically. DA autoreceptor function is eliminated in D_2 KO mice,[122] although interestingly the effects of AMPH on DA release were unaltered in that study. Interpretation of psychomotor stimulant effects in D_2 KO mice is complicated by reduced basal levels of activity.[137] However, even when this is taken into account they do appear to display diminished locomotor-stimulant effects of METH,[138] although sensitization of those responses did not appear to be affected.

D_3, D_4, and D_5 KO mice. As for cocaine, both D_3 and D_4 KO mice have increased locomotor-stimulant effects of AMPH,[126,139] although this is limited to particular doses.[140] Importantly, these changes in D_3 KO mice were not associated with changes in the stereotypical effects of AMPH,[140] as might be predicted based on the localization of that receptor compared to the D_2 receptor. D_4 KO mice also have increased locomotor responses to METH.[128] The mechanisms may be different in each case, as discussed earlier, and may or may not involve other DA receptors. Locomotor sensitization to AMPH is also enhanced in D_4 KO mice,[139] at least under some conditions. AMPH sensitization was not different from WT controls in D_5 KO mice.[141]

The PPI-impairing effects of AMPH were disrupted in D_2 KO mice but not D_3 or D_4 KO mice.[142] This pattern is slightly different from that discussed earlier for cocaine. This is a further indication that the effects of psychostimulants, though substantially overlapping, still involve some different mechanisms. The effect of AMPH was not disrupted in D_{2L} KO mice, which may suggest that these effects are mediated by the D_{2S} isoform.[143]

Adverse effects of AMPH. Evidence for the importance of DA in the adverse effects of METH was discussed earlier, including data from DAT KO mice, including evidence that the hyperthermic and lethal effects of METH were somewhat dissociable. DA antagonists reduce METH-induced hyperthermia[73] and lethality,[74] but these effects are highly dose dependent and substantially dependent on ambient temperature. In a recent study, we examined the roles of dopamine D_1 and D_2 receptors in METH-induced hyperthermia and lethal effects by using D_1 KO and D_2 KO mice.[144] This study found that both the D_1 and D_2 receptors have roles in the lethal effects of METH but differently affect the hyperthermic effects of METH. D_2 KO eliminated METH-induced hyperthermia, whereas D_1 KO produced a more modest attenuation of this response. Both KOs produced a substantial attenuation of METH-induced lethality. These data further dissociate the mechanisms underlying METH-induced lethality and METH-induced hyperthermia, even though dopaminergic mechanisms appear to be involved in both effects.

MDMA. Most research into the mechanisms underlying the effects of MDMA has concentrated on serotonergic mechanisms, but there is also evidence for direct or indirect roles of dopaminergic systems in MDMA-induced effects, although not much work has been done in this area in transgenic mice. In male D_1 KO mice the locomotor stimulant effects of MDMA were increased, whereas D_2 KO was found to reduce MDMA effects and D_3 KO was without effect.[145] There were also some changes in the pattern of activity, including reduced MDMA-induced perseverative thigmotaxis in D_2 KO mice. There was also some sex dependency of these effects, so although D_3 KO was without effect in males, there was a slight reduction in MDMA-induced hyperlocomotion in females.

Serotonin receptors

Although the importance of dopaminergic systems in the effects of psychostimulants has been well established, data discussed earlier indicate that serotonergic systems, particularly those that interact with dopaminergic systems, also have a role. That evidence has not identified the particular parts of the serotonergic system that may be involved in psychostimulant actions and which of the many 5-HT receptor subtypes may be involved. 5-HT receptors are diverse, comprising many structurally and pharmacologically distinct mammalian 5-HT receptor subtypes, as determined from sequence homology and pharmacology,[146] which have distinctly different anatomical distributions,[147–149] and many of which are thought to modulate the effects of psychostimulants.[150] Although pharmacological evidence has been important in implicating 5-HT in the effects of many psychostimulants, because of the many 5-HT receptor subtypes the situation regarding specificity of available agents is even more of a problem than it is for dopaminergic systems. Therefore, transgenic studies have contributed substantially to our knowledge about the role of specific 5-HT receptor subtypes in the effects of psychostimulants, although some have been much more thoroughly investigated than others.

Cocaine

5-HT_{1B} KO mice. On the basis of the impetus of pharmacological evidence, the 5-HT_{1B} receptor has been more extensively examined in transgenic studies than other 5-HT receptor subtypes. This evidence includes data demonstrating that 5-HT_{1B} receptor agonists enhance cocaine-induced reinforcement[151] and increase extracellular DA in the nucleus accumbens.[152] 5-HT_{1B} KO increased the locomotor stimulant effects of cocaine,[15,153] which prompted Rocha *et al.*[15] to suggest that these mice were "presensitized" to cocaine. 5-HT_{1B} KO was initially associated with accelerated acquisition of cocaine self-administration,[154] without many other changes, but was subsequently associated with increased cocaine self-administration under a variety of conditions.[15,153] Surprisingly, cocaine was reported not to produce a CPP in these mice,[155] although this appears to be yet another example in which transgenic manipulations produce divergent results in CPP and self-administration paradigms. Nonetheless, as further evidence that these effects involved interactions with dopaminergic systems, *in vivo* microdialysis studies found that basal and cocaine-evoked DA levels in the nucleus accumbens of 5-HT_{1B} KO mice were increased.[156] These changes would appear to be most consistent with the self-administration studies in these mice, although there is evidence that postsynaptic changes may oppose these actions, including reduced cocaine-evoked elevation of c-Fos,[157] which may help explain the divergent effects in different models.

Other serotonin receptors. Other 5-HT receptor subtypes have been much less extensively examined in transgenic models, the initial studies beginning with 5-HT receptor subtypes localized on dopaminergic neurons and for which there was already evidence that they modulate dopaminergic function.[158] Deletion of 5-HT_{2C} receptors was associated with greater release of DA in the nucleus accumbens and increased reinforcing efficacy of cocaine, including increased responding under a progressive ratio schedule.[159] In both 5-HT_{1B} receptor KO mice and in 5-HT_{2C} receptor KO mice, higher reinforcing efficacy of cocaine was associated with greater cocaine-stimulated DA levels in the nucleus accumbens. Thus studies of cocaine self-administration in different 5-HT receptor KO mice suggest that increased reinforcing efficacy of cocaine is ultimately associated with increased DA activity.

Some other 5-HT receptor subtypes have also been examined. The locomotor-stimulating effects of cocaine are increased in 5-HT_{2A} KO mice, but they still exhibit sensitization.[160] Transgenic overexpression of the 5-HT_3 receptor reduces the rewarding effects of cocaine in the CPP paradigm.[161] In these data there was a slight trend for 5-HT_3-overexpressing mice to be more sensitive to low doses of cocaine. The 50% effective dose for locomotor-stimulating effects of cocaine was substantially reduced in these mice, which was associated with greater DA release in response to application of low doses of cocaine to striatal brain slices. The contribution of specific serotonergic receptors to the toxic or lethal effects of cocaine has not been investigated to any great degree, although a recent study has shown that 5-HT_7 KO increases cocaine-induced seizures and lethality.[162]

Amphetamines

Other psychostimulants have been even less examined than cocaine in 5-HT receptor KO mice. 5-HT_{1B} KO mice had increased acute and sensitized locomotor effects of AMPH.[163] On the basis of comparisons between intraperitoneal and intravenous routes of administration, those authors suggested that some of the effects of 5-HT_{1B} KO were due to interactions with handling stress, but not all. As for cocaine, the 50% effective dose for the locomotor-stimulating effects of METH was decreased in 5-HT_3-overexpressing mice.[161] Finally, MDMA does not affect PPI in WT mice but increases PPI in 5-HT_{1B} KO mice,[164,165] whereas the locomotor stimulant effects of MDMA are attenuated in 5-HT_{1B} KO mice.[166]